

10/20/00
PTO

Express Mail Label No. EL 605314152US

10-23-00

A

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
13115Total Pages in this Submission
62**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

Method of Inducing and/or Enhancing an Immune Response to Tumor Antigens

and invented by:

Neil Bernstein; James Tartaglia; Philippe Moingeon; Brian BarberJC914 U.S. PTO
09/693754
10/20/00**If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:** Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Which is a:

 Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Which is a:

 Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. Filing fee as calculated and transmitted as described below

2. Specification having 47 pages and including the following:
 - a. Descriptive Title of the Invention
 - b. Cross References to Related Applications (*if applicable*)
 - c. Statement Regarding Federally-sponsored Research/Development (*if applicable*)
 - d. Reference to Microfiche Appendix (*if applicable*)
 - e. Background of the Invention
 - f. Brief Summary of the Invention
 - g. Brief Description of the Drawings (*if drawings filed*)
 - h. Detailed Description
 - i. Claim(s) as Classified Below
 - j. Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

13115

Total Pages in this Submission

62

Application Elements (Continued)

3. Drawing(s) (*when necessary as prescribed by 35 USC 113*)
 - a. Formal Number of Sheets _____
 - b. Informal Number of Sheets 11
4. Oath or Declaration
 - a. Newly executed (*original or copy*) Unexecuted
 - b. Copy from a prior application (37 CFR 1.63(d)) (*for continuation/divisional application only*)
 - c. With Power of Attorney Without Power of Attorney
 - d. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. Incorporation By Reference (*usable if Box 4b is checked*)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. Computer Program in Microfiche (*Appendix*)
7. Nucleotide and/or Amino Acid Sequence Submission (*if applicable, all must be included*)
 - a. Paper Copy
 - b. Computer Readable Copy (*identical to computer copy*)
 - c. Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. Assignment Papers (*cover sheet & document(s)*)
9. 37 CFR 3.73(B) Statement (*when there is an assignee*)
10. English Translation Document (*if applicable*)
11. Information Disclosure Statement/PTO-1449 Copies of IDS Citations
12. Preliminary Amendment
13. Acknowledgment postcard
14. Certificate of Mailing
 First Class Express Mail (*Specify Label No.:* EL605314152US)

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
13115

Total Pages in this Submission
62

Accompanying Application Parts (Continued)

15. Certified Copy of Priority Document(s) (*if foreign priority is claimed*)

16. Additional Enclosures (*please identify below*):

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

17. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
13115


Total Pages in this Submission
62

Fee Calculation and Transmittal

CLAIMS AS FILED

| For | #Filed | #Allowed | #Extra | Rate | Fee |
|---|--------------------------|----------|--------|-----------|----------------------------------|
| Total Claims | 19 | - 20 = | 0 | x \$18.00 | \$0.00 |
| Indep. Claims | 1 | - 3 = | 0 | x \$80.00 | \$0.00 |
| Multiple Dependent Claims (check if applicable) | <input type="checkbox"/> | | | | |
| | | | | | \$0.00 |
| | | | | | BASIC FEE \$710.00 |
| OTHER FEE (specify purpose) | | | | | \$0.00 |
| | | | | | TOTAL FILING FEE \$710.00 |

- A check in the amount of _____ to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge and credit Deposit Account No. 11-0171 as described below. A duplicate copy of this sheet is enclosed.
- Charge the amount of \$710.00 as filing fee.
- Credit any overpayment.
- Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).



John J. Santalone
Signature

Dated: October 20, 2000

John J. Santalone, Esq.
Reg. No. 32,794

cc: Kalow & Springut LLP
488 Madison Avenue, 19th Floor
New York, New York 10022

B&P File No 11014-15/MG

BERESKIN & PARR

UNITED STATES

**Method of Inducing and/or Enhancing an
Immune Response to Tumor Antigens**

Inventors: Neil Berinstein, James Tartaglia, Philippe Moingeon
and Brian Barber

1

**TITLE: Method of Inducing and/or Enhancing an Immune Response to
Tumor Antigens**

This application claims the benefit of United States application serial
5 no 60/160,879, filed on October 22, 1999 and United States application
serial no. 60/223,325 filed on August 7, 2000, both of which are incorporated
by reference herein.

FIELD OF THE INVENTION

The present invention relates to methods for inducing and/or
10 enhancing immune responses to tumor antigens.

BACKGROUND OF THE INVENTION

Using immunological approaches to cancer therapy has been difficult
as tumor cells are self-derived and therefore not as immunogenic as
exogenous agents such as bacteria and viruses. As a result, the prospects
15 of cancer immunotherapy rely upon the identification of tumor associated
antigens ("TAA") which can be recognized by the immune system.
Specifically, target antigens eliciting T cell-mediated responses are of
critical interest. This comes from evidence that cytotoxic T lymphocytes
(CTLs) can induce tumor regression both in animal models (Kast W. et al
20 (1989) *Cell* 59:6035; Greendberg P. (1991) *Adv. Immunol.* 49:281) and in
humans (Boon T. et al. (1994) *Annu. Rev. Immunol.* 12:337). To date, many
tumor associated antigens have been identified. These include the antigens
MAGE, BAGE, GAGE, RAGE, gp100, MART-1/Melan-A, tyrosinase,
carcinoembryonic antigen (CEA) as well as many others (Horig and
25 Kaufman (1999) *Clinical Immunology* 92:211-223). Some of these tumor
associated antigens are discussed below.

The first human tumor associated antigen characterized was
identified from a melanoma. This antigen (originally designated MAGE 1)

was identified using CTLs isolated from an HLA A1+ melanoma patient to screen HLA A1 target cells transfected with tumor DNA (van der Bruggen P. (1991) *Science*, 254:1643; these tumor associated antigens are now designated MAGE-A1, MAGE-A2, etc.). Interestingly, MAGE 1 was found to belong to a family of at least 12 closely related genes located on the X chromosome (de Plaen, E. et al. (1994) *Immunogenetics* 40:360). The nucleic acid sequence of the 11 additional MAGE genes share 65-85% identity with that of MAGE-1 (de Smet, C. et al. (1994) *Immunogenetics* 39:121). Both MAGE 1 and 3 are present in normal tissues, but expressed only in the testis (de Plaen, E. et al. (1994) *Supra*; de Smet, C. et al. (1994) *Supra*; Takahashi, K. et al. (1995) *Cancer Res.* 55:3478; Chyomey, P. et al. (1995) *Immunogenetics* 43:97). These initial results have subsequently been extended with the identification of new gene families (i.e. RAGE, BAGE, GAGE), all of which are typically not expressed in normal tissues (except testis) but expressed in a variety of tumor types.

Human carcinoembryonic antigen (CEA) is a 180 kD glycoprotein expressed on the majority of colon, rectal, stomach and pancreatic tumors (Muaro et al. (1985) *Cancer Res.* 45:5769), some 50% of breast carcinomas (Steward et al. (1974) *Cancer* 33:1246) and 70% of lung carcinomas (Vincent, R G. and Chu, T.M. (1978) *J. Thor. Cardiovas. Surg.* 66:320). CEA was first described as a cancer specific fetal antigen in adenocarcinoma of the human digestive tract in 1965 (Gold, P. and Freeman, S.O. (1965) *Exp. Med.* 121:439). Since that time, CEA has been characterized as a cell surface antigen produced in excess in nearly all solid tumors of the human gastrointestinal tract. The gene for the human CEA protein has been cloned (Oikawa et al (1987) *Biochim. Biophys. Res.* 142:511-518; European Application No. EP 0346710). CEA is also expressed in fetal gut tissue and to a lesser extent on normal colon epithelium. The immunogenicity of CEA

has been ambiguous, with several studies reporting the presence of anti-CEA antibodies in patients (Gold et al (1973) *Nature New Biology* 239:60; Pompecki, R. (1980) *Eur. J. Cancer* 16:973; Ura et al (1985) *Cancer Lett.* 25:283; Fuchs et al. (1988) *Cancer Immunol. Immunother.* 26:180) while other studies have not (LoGerfo et al. (1972) *Int. J. Cancer* 9:344; MacSween, J.M. (1975) *Int. J. Cancer* 15:246; Chester K.A. and Begent, H.J. (1984) *Clin. Exp. Immunol.* 58:685).

Gp100 is normally found in melanosomes and expressed in melanocytes, retinal cells, and other neural crest derivatives. The function of gp100 is currently unknown. By mass spectrometry, three immunodominant HLA-A2 binding gp100 epitopes have been identified: g9-154 (amino acids 154-162), g9-209 (amino acids 209-217); and g9-280 (amino acids 280-288). Notably, two of these epitopes (as peptides) have been synthetically altered so as to induce a more vigorous immune response in the original T cell clone: the threonine at position 2 in gp-209 was changed to a methionine, and the alanine residue at position 9 in gp-280 was changed to a valine. These changes increase the binding affinity of the epitope-peptides to the HLA-A2 molecule without changing the intrinsic natural epitopes recognized by the T cell receptor (TCR). Rosenberg and colleagues (NIH) have already successfully immunized melanoma patients with one of these modified peptides and have reported achieving objective clinical responses in some patients.

Despite significant advances that have been made with respect to immunological approaches to cancer treatment, there is still a need in the art to improve cancer immunotherapies.

SUMMARY OF THE INVENTION

The present invention relates to improved methods for inducing and/or enhancing an immune response to a tumor antigen.

The present inventors have found that administering the tumor antigen or nucleic acid coding therefor directly into a lymphatic site (such as a lymph node) induces and/or significantly enhances the immune response to the tumor antigen and/or breaks tolerance to the tumor antigen, both 5 which have been a major challenge in previous methods of cancer immunotherapy.

Accordingly, one aspect the present invention provides a method for inducing and/or enhancing an immune response in an animal to a tumor antigen comprising administering an effective amount of a tumor antigen, 10 nucleic acid coding therefor, vector or cell comprising said nucleic acid, or vaccine comprising the aforementioned to a lymphatic site in the animal.

In another aspect, the present invention provides a method for breaking immune tolerance to a tumor antigen in an animal comprising administering an effective amount of a tumor antigen, nucleic acid coding 15 therefor, vector or cell comprising said nucleic acid, or vaccine comprising the aforementioned to a lymphatic site in the animal.

Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while 20 indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

25 The invention will now be described in relation to the drawings in which:

Figure 1 is a bar graph showing the results of an IFN- γ -ELISPOT analysis of an animal receiving an intranodal injection of the tumor antigen

Figure 2 is a bar graph showing the results of an IFN- γ -ELISPOT analysis of an animal receiving an intranodal injection of the tumor antigen

Figure 3 is a bar graph showing the results of an IFN- γ -ELISPOT analysis of an animal receiving a subcutaneous injection of the tumor antigen.

Figure 4 is a bar graph showing the results of an IFN- γ -ELISPOT analysis of an animal receiving a subcutaneous injection of the tumor antigen.

Figure 5 is a graph showing the antibody response after a regimen of intranodal (group 2) and subcutaneous (group 3) administration of ALVAC-modified gp100/modified gp100 peptide immunogens

Figure 6 is the nucleic acid sequence of a modified gp100M cDNA (SEQ.ID.NO.:109).

Figure 7 is the deduced amino acid sequence of the modified gp100M protein (SEQ.ID.NO.:110)

Figure 8 is the nucleic acid and amino acid sequence of a modified CEA (SEQ.ID.NOS.: 111 and 112).

DETAILED DESCRIPTION OF THE INVENTION

As hereinbefore mentioned, the present invention relates to an improved method for inducing and/or enhancing the immune response to a tumor antigen. Accordingly, the present invention provides a method for inducing and/or enhancing an immune response in an animal to a tumor antigen comprising administering an effective amount of a tumor antigen, a nucleic acid sequence encoding a tumor antigen, a vector or cell comprising the nucleic acid sequence, or a vaccine comprising the tumor antigen, the nucleic acid sequence encoding the tumor antigen, or a vector comprising the nucleic acid sequence encoding the tumor antigen to a lymphatic site in the animal.

The term "inducing and/or enhancing an immune response" means that the method evokes and/or enhances any response of the animal's immune system.

"Immune response" is defined as any response of the immune system, for example, of either a cell-mediated (i.e. cytotoxic T-lymphocyte mediated) or humoral (i.e. antibody mediated) nature. These immune responses can be assessed by a number of *in vivo* or *in vitro* assays well known to one skilled in the art including, but not limited to, antibody assays (for example ELISA assays) antigen specific cytotoxicity assays, production 10 of cytokines (for example ELISPOT assays), regression of tumors expressing the tumor antigens, inhibition of cancer cells expressing the tumor antigens, etc..

The term "lymphatic site" means a site in the body that is associated with the lymphatic system including lymphatic organs, tissues, cells, nodes 15 or glands such as spleen, thymus, tonsils, Peyer's patches, bone marrow, lymphocytes, thoracic duct as well as all of the lymph nodes of the body.

The term "animal" as used herein includes all members of the animal kingdom and is preferably human.

The term "effective amount" as used herein means an amount 20 effective, at dosages and for periods of time necessary to achieve the desired results.

The term "tumor antigen" as used herein includes both tumor associated antigens (TAAs) and tumor specific antigens (TSAs). A tumor associated antigen means an antigen that is expressed on the surface of a 25 tumor cell in higher amounts than is observed on normal cells or an antigen that is expressed on normal cells during fetal development. A tumor specific antigen is an antigen that is unique to tumor cells and is not expressed on normal cells. The term tumor antigen includes TAAs or TSAs

that have been already identified and those that have yet to be identified and includes fragments, epitopes and any and all modifications to the tumor antigens.

- The tumor associated antigen can be any tumor associated antigen
- 5 including, but not limited to, gp100 (Kawakami et al., *J. Immunol.* 154:3961-3968 (1995); Cox et al., *Science*, 264:716-719 (1994)), MART - 1/Melan A (Kawakami et al., *J. Exp. Med.*, 180:347-352 (1994); Castelli et al., *J. Exp. Med.*, 181:363-368 (1995)), gp75 (TRP-1) (Wang et al., *J. Exp. Med.*, 186:1131-1140 (1996)), and Tyrosinase (Wolfel et al., *Eur. J. Immunol.*, 24:759-764 (1994); Topalian et at., *J. Exp. Med.*, 183:1965-1971 (1996)); melanoma proteoglycan (Hellstrom et al., *J. Immunol.*, 130:1467-1472 (1983); Ross et al., *Arch. Biochem Biophys.*, 225:370-383 (1983)); tumor-specific, widely shared antigens, for example: antigens of MAGE family, for example, MAGE-1, 2,3,4,6, and 12 (Van der Bruggen et al., *Science*, 254:1643-1647 (1991)); Rogner et al., *Genomics*, 29:729-731 (1995)), antigens of BAGE family (Boel et al., *Immunity*, 2:167-175 (1995)), antigens of GAGE family, for example, GAGE-1,2 (Van den Eynde et al., *J. Exp. Med.*, 182:689-698 (1995)), antigens of RAGE family, for example, RAGE-1 (Gaugler et at., *Immunogenetics*, 44:323-330 (1996)), N-
- 10 acetylglucosaminyltransferase-V (Guilloux et at., *J. Exp. Med.*, 183:1173-1183 (1996)), and p15 (Robbins et al., *J. Immunol.* 154:5944-5950 (1995)); tumor specific mutated antigens; mutated β -catenin (Robbins et al., *J. Exp. Med.*, 183:1185-1192 (1996)), mutated MUM-1 (Coulie et al., *Proc. Natl. Acad. Sci. USA*, 92:7976-7980 (1995)), and mutated cyclin dependent
- 15 kinases-4 (CDK4) (Wolfel et al., *Science*, 269:1281-1284 (1995)); mutated oncogene products: p21 ras (Fossum et at., *Int. J. Cancer*, 56:40-45 (1994)), BCR-abl (Bocchia et al., *Blood*, 85:2680-2684 (1995)), p53 (Theobald et al., *Proc. Natl. Acad. Sci. USA*, 92:11993-11997 (1995)), and p185 HER2/neu
- 20
- 25

(Fisk et al., *J. Exp. Med.*, 181:2109-2117 (1995)); Peoples et al., *Proc. Natl. Acad. Sci., USA*, 92:432-436 (1995); mutated epidermal growth factor receptor (EGFR) (Fujimoto et al., *Eur. J. Gynecol. Oncol.*, 16:40-47 (1995)); Harris et al., *Breast Cancer Res. Treat.*, 29:1-2 (1994)); carcinoembryonic antigens (CEA) (Kwong et al., *J. Natl. Cancer Inst.*, 85:982-990 (1995)); carcinoma associated mutated mucins, for example, MUC-1 gene products (Jerome et al., *J. Immunol.*, 151:1654-1662 (1993), Ioannides et al., *J. Immunol.*, 151:3693-3703 (1993), Takahashi et al., *J. Immunol.*, 153:2102-2109 (1994)); EBNA gene products of EBV, for example, EBNA-1 gene product (Rickinson et al., *Cancer Surveys*, 13:53-80 (1992)); E7, E6 proteins of human papillomavirus (Ressing et al., *J. Immunol.*, 154:5934-5943 (1995)); prostate specific antigens (PSA) (Xue et al., *The Prostate*, 30:73-78 (1997)); prostate specific membrane antigen (PSMA) (Israeli, et al., *Cancer Res.*, 54:1807-1811 (1994)); PCTA-1 (Sue et al., *Proc. Natl. Acad. Sci. USA*, 93:7252-7257 (1996)); idiotypic epitopes or antigens, for example, immunoglobulin idiotypes or T cell receptor idiotypes, (Chen et al., *J. Immunol.*, 153:4775-4787 (1994); Syrengelas et al., *Nat. Med.*, 2:1038-1040 (1996)); KSA (US Patent # 5348887); NY-ESO-1 (WO 98/14464).

Also included are modified tumor antigens and/or epitope/peptides derived therefrom (both unmodified and modified). Examples include, but are not limited to, modified and unmodified epitope/peptides derived from gp100 (WO 98/02598; WO 95/29193; WO 97/34613; WO 98/33810; CEA (WO 99/19478; S. Zaremba et al. (1997) *Cancer Research* 57:4570-7; K.T. Tsang et al. (1995) *J. Int. Cancer Inst.* 87:982-90); MART-1 (WO 98/58951, WO 98/02538; D. Valmari et al. (2000) *J. Immunol.* 164:1125-31); p53 (M. Eura et al. (2000) *Clinical Cancer Research* 6:979-86); TRP-1 and TRP-2 (WO 97/29195); tyrosinase (WO 96/21734, WO 97/11669; WO 97/34613; WO 98/33810; WO 95/23234; WO 97/26535); KSA (WO 97/15597); PSA (WO

96/40754); NY-ESO 1 (WO 99/18206); HER2/neu (US Patent #5869445); MAGE family related (L. Heidecker et al. (2000) *J. Immunol.* 164:6041-5; WO 95/04542; WO 95/25530; WO 95/25739; WO 96/26214; WO 97/31017; WO 98/10780).

5 In a preferred embodiment, the tumor-associated antigen is gp100, a modified gp100 or a fragment thereof. In particular, the inventors have prepared a modified gp100 peptide termed gp100M which has the nucleic acid sequence shown in Figure 6 (SEQ.ID.NO.:109) and the deduced amino acid sequence shown in Figure 7 (SEQ.ID.NO.:110). The inventors have
10 shown that the intranodal injection of a recombinant avipox virus comprising a nucleic acid coding for fragments of the modified gp100 (comprising modified epitopes 209(2M) (IMDQVPFSY, SEQ.ID.NO.:1) and 290(9V) (YLEPGPVT, SEQ.ID.NO.:2)) followed by modified epitope/peptide boosts induced both a humoral and cell mediated response that was several times
15 higher than when the same antigens were administered subcutaneously.
The experimental details and results are discussed in Example 1.

In another embodiment, the tumor-associated antigen is carcinoembryonic antigen (CEA), a modified CEA or a fragment thereof. The nucleic acid sequence of a modified CEA antigen is shown in Figure 8 and
20 SEQ.ID.NO.:111. The corresponding amino acid sequence is shown in Figure 8 and SEQ.ID.NO.:112. Preferably, the modified CEA antigen comprises the sequence YLSGADLNL, SEQ.ID.NO.:113.

Additional embodiments of the invention encompass nucleic acid sequences comprising sequences encoding the tumor antigens and
25 fragments or modified forms thereof as hereinbefore described. The term "nucleic acid sequence" refers to a sequence of nucleotide or nucleoside monomers consisting of naturally occurring bases, sugars and intersugar (backbone) linkages. The term also includes modified or substituted sequences comprising non-naturally occurring monomers or portions
30 thereof, which function similarly. The nucleic acid sequences of the present

invention may be ribonucleic (RNA) or deoxyribonucleic acids (DNA) and may contain naturally occurring bases including adenine, guanine, cytosine, thymidine and uracil. The sequences may also contain modified bases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl, 2-propyl, and 5 other alkyl adenines, 5-halo uracil, 5-halo cytosine, 6-aza uracil, 6-aza cytosine and 6-aza thymine, pseudo uracil, 4-thiouracil, 8-halo adenine, 8-amino adenine, 8-thiol adenine, 8-thio-alkyl adenines, 8-hydroxyl adenine and other 8-substituted adenines, 8-halo guanines, 8-amino guanine, 8-thiol guanine, 8-thioalkyl guanines, 8-hydroxyl guanine and other 8-substituted guanines, other aza and deaza uracils, thymidines, cytosines, adenines, or guanines, 5-trifluoromethyl uracil and 5-trifluoro cytosine.

The nucleic acid sequences encoding the tumor antigens of the invention include, but are not limited to, viral nucleic acid(s), plasmid(s), bacterial DNA, naked/free DNA and RNA. The nucleic acids encompass both single and double stranded forms. As such, these nucleic acids comprise the relevant base sequences coding for the aforementioned tumor antigens. For purposes of definitiveness, the "relevant base sequences coding for the aforementioned polypeptides" further encompass complementary nucleic acid sequences. As such, embodiments of the invention encompass nucleic acid sequences *per se* encoding for the aforementioned tumor antigens, or recombinant nucleic acids into which has been inserted said nucleic acids coding for tumor antigens (as described below).

Bacterial DNA useful in recombinant nucleic acid embodiments of the invention are known to those of ordinary skill in the art. Sources of bacterial DNA include, for example, *Shigella*, *Salmonella*, *Vibrio cholerae*, *Lactobacillus*, *Bacille Calmette Guérin (BCG)*, and *Streptococcus*. In bacterial DNA embodiments of the invention, nucleic acid of the invention may be inserted into the bacterial genome, can remain in a free state, or be carried on a plasmid.

Viral recombinant nucleic acid embodiments of the invention may be derived from a poxvirus or other virus such as adenovirus or alphavirus.

Preferably the viral nucleic acid is incapable of integration in recipient animal cells. The elements for expression from said nucleic acid may include a promoter suitable for expression in recipient animal cells.

Specific viral recombinant nucleic acid embodiments of the invention 5 encompass (but are not limited to) poxviral, alphaviral, and adenoviral nucleic acid. Poxviral nucleic acid may be selected from the group consisting of avipox, orthopox, and suipox nucleic acid. Particular embodiments encompass poxviral nucleic acid selected from vaccinia, fowlpox, canary pox and swinepox; specific examples include TROVAC, 10 NYVAC, ALVAC, MVA, Wyeth and Poxvac-TC (described in more detail below).

It is further contemplated that recombinant nucleic acids of this invention may further comprise nucleic acid sequences encoding at least one member chosen from the group consisting of cytokines, lymphokines, 15 and co-stimulatory molecules. Examples include (but are not limited to) interleukin 2, interleukin 12, interleukin 6, interferon gamma, tumor necrosis factor Alpha, GM-CSF, B7.1, B7.2, ICAM-1, LFA-3, and Cd72.

Standard techniques of molecular biology for preparing and purifying 20 nucleic acids well known to those skilled in the art can be used in the preparation of the recombinant nucleic acid aspects of the invention (for example, as taught in *Current Protocols in Molecular Biology*, F.M. Ausubel et al. (Eds.), John Wiley and Sons, Inc, N.Y., U.S.A. (1998), Chpts. 1, 2 and 4; *Molecular Cloning: A Laboratory Manual* (2nd Ed.), J. Sambrook, E.F. Fritsch and T. Maniatis (Eds.), Cold Spring Harbor Laboratory Press, N.Y., U.S.A. 25 (1989), Chpts. 1, 2, 3 and 7).

Aspects of this invention further encompass vectors comprising the aforementioned nucleic acids. In certain embodiments, said vectors may be recombinant viruses or bacteria (as described below)

Adenovirus vectors and methods for their construction have been 30 described (e.g. U.S. Patent Nos 5994132, 5932210, 6057158 and Published PCT Applications WO 9817783, WO 9744475, WO 9961034, WO 9950292, WO 9927101, WO 9720575, WO 9640955, WO 9630534-all of

which are herein incorporated by reference). Alphavirus vectors have also been described in the art and can be used in embodiments of this invention (e.g. U.S. Patent Nos. 5792462, 5739026, 5843723, 5789245, and Published PCT Applications WO 9210578, WO 9527044, WO 9531565, WO 5 9815636-all of which are herein incorporated by reference), as have lentivirus vectors (e.g. U.S. Patent Nos. 6013516, 5994136 and Published PCT Applications WO 9817816, WO 9712622, WO 9817815, WO 9839463, WO 9846083, WO 9915641, WO 9919501, WO 9930742, WO 9931251, WO 9851810, WO 0000600-all of which are herein incorporated by reference).

10 Poxvirus vectors that can be used include, for example, avipox, orthopox or suipox poxvirus (as described in U.S. Patent Nos. 5364773, 4603112, 5762938, 5378457, 5494807, 5505941, 5756103, 5833975 and 5990091-all of which are herein incorporated by reference). Poxvirus vectors comprising a nucleic acid coding for a tumor antigen can be obtained by 15 homologous recombination as is known to one skilled in the art. As such, the nucleic acid coding for the tumor antigen is inserted into the viral genome under appropriate conditions for expression in mammalian cells (as described below).

In one embodiment of the invention the poxvirus vector is ALVAC (1) 20 or ALVAC (2) (both of which have been derived from canarypox virus). ALVAC (1) (or ALVAC (2)) does not productively replicate in non-avian hosts, a characteristic thought to improve its safety profile. ALVAC (1) is an attenuated canarypox virus-based vector that was a plaque-cloned derivative 25 of the licensed canarypox vaccine, Kanapox (Tartaglia et al. (1992) *Virology* 188:217; U.S. Patent Nos. 5505941, 5756103 and 5833975-all of which are incorporated herein by reference). ALVAC (1) has some general properties which are the same as some general properties of Kanapox. ALVAC-based recombinant viruses expressing extrinsic immunogens have also been demonstrated efficacious as vaccine vectors (Tartaglia et al. In AIDS 30 Research Reviews (vol. 3) Koff W, Wong-Staal F. and Kennedy R.C. (eds.), Marcel Dekker NY, pp. 361-378 (1993a), Tartaglia, J. et al. (1993b) *J. Virol.* 67:2370). For instance, mice immunized with an ALVAC (1) recombinant

13

expressing the rabies virus glycoprotein were protected from lethal challenge with rabies virus (Tartaglia, J et al., (1992) *supra*) demonstrating the potential for ALVAC (1) as a vaccine vector. ALVAC-based recombinants have also proven efficacious in dogs challenged with canine distemper virus (Taylor, J. et al (1992) *Virology* 187:321) and rabies virus (Perkus, M.E. et al., In Combined Vaccines and Simultaneous Administration: Current Issues and Perspective, Annals of the New York Academy of Sciences (1994)), in cats challenged with feline leukemia virus (Tartaglia, J. et al., (1993b) *supra*), and in horses challenged with equine influenza virus (Taylor, J. et al., In Proceedings of the Third International Symposium on Avian Influenza, Univ. of Wisconsin-Madison, Madison, Wisconsin, pp. 331-335 (1993)).

ALVAC (2) is a second-generation ALVAC vector in which vaccinia transcription elements E3L and K3L have been inserted within the C6 locus (U.S. Patent No. 5990091, incorporated herein by reference). The E3L encodes a protein capable of specifically binding to dsRNA. The K3L ORF has significant homology to E1F-2. Within ALVAC (2) the E3L gene is under the transcriptional control of its natural promoter, whereas K3L has been placed under the control of the early/late vaccine H6 promoter. The E3L and K3L genes act to inhibit PKR activity in cells infected with ALVAC (2), allowing enhancement of the level and persistence of foreign gene expression.

Additional viral vectors encompass natural host-restricted poxviruses. Fowlpox virus (FPV) is the prototypic virus of the Avipox genus of the Poxvirus family. Replication of avipox viruses is limited to avian species (Matthews, R.E.F. (1982) *Intervirology* 17:42) and there are no reports in the literature of avipox virus causing a productive infection in any non-avian species including man. This host restriction provides an inherent safety barrier to transmission of the virus to other species and makes use of avipox virus based vectors in veterinary and human applications an attractive proposition.

FPV has been used advantageously as a vector expressing immunogens from poultry pathogens. The hemagglutinin protein of a virulent avian influenza virus was expressed in an FPV recombinant. After inoculation of the recombinant into chickens and turkeys, an immune response was induced which was protective against either a homologous or a heterologous virulent influenza virus challenge (Taylor, J. et al (1988) Vaccine 6: 504) FPV recombinants expressing the surface glycoproteins of Newcastle Disease Virus have also been developed (Taylor, J. et al. (1990) *J. Virol.* 64:1441; Edbauer, C. et al. (1990) *Virology* 179:901; U.S. Patent No. 5766599-incorporated herein by reference).

A highly attenuated strain of vaccinia, designated MVA, has also been used as a vector for poxvirus-based vaccines. Use of MVA is described in U.S. Patent No. 5,185,146.

Other attenuated poxvirus vectors have been prepared via genetic modification to wild type strains of vaccinia. The NYVAC vector, for example, is derived by deletion of specific virulence and host-range genes from the Copenhagen strain of vaccinia (Tartaglia, J. et al. (1992), *supra*; U.S. Patent Nos. 5364773 and 5494807-incorporated herein by reference) and has proven useful as a recombinant vector in eliciting a protective immune response against expressed foreign antigens.

Recombinant viruses can be constructed by processes known to those skilled in the art (for example, as previously described for vaccinia and avipox viruses; U.S. Patent Nos. 4769330; 4722848; 4603112; 5110587; and 5174993-all of which are incorporated herein by reference).

In further embodiments of the invention, live and/or attenuated bacteria may also be used as vectors. For example, non-toxicogenic *Vibrio cholerae* mutant strains may be useful as bacterial vectors in embodiments of this invention; as described in US Patent No. 4,882,278 (disclosing a strain in which a substantial amount of the coding sequence of each of the two *ctxA* alleles has been deleted so that no functional cholera toxin is produced), WO 92/11354 (strain in which the *irgA* locus is inactivated by mutation, this mutation can be combined in a single strain with *ctxA*

mutations), and WO 94/1533 (deletion mutant lacking functional *cpxA* and *attRS1* DNA sequences). These strains can be genetically engineered to express heterologous antigens, as described in WO 94/19482. (All of the aforementioned issued patent/patent applications are incorporated herein by reference.)

Attenuated *Salmonella typhimurium* strains, genetically engineered for recombinant expression of heterologous antigens and their use as oral immunogens are described, for example, in WO 92/11361.

As noted, those skilled in the art will readily recognize that other bacterial strains useful as bacterial vectors in embodiments of this invention include (but are not limited to) *Shigella flexneri*, *Streptococcus gordonii*, and Bacille Calmette Guerin (as described in WO 88/6626, WO 90/0594, WO 91/13157, WO 92/1796, and WO 92/21376; all of which are incorporated herein by reference). In bacterial vector embodiments of this invention, a nucleic acid coding for a tumor antigen may be inserted into the bacterial genome, can remain in a free state, or be carried on a plasmid.

It is further contemplated that the invention encompasses vectors which comprise nucleic acids coding for at least one member from the group consisting of cytokines, lymphokines and immunostimulatory molecules. Said nucleic acid sequences can be contiguous with sequences coding for the tumor antigen or encoded on distinct nucleic acids.

Cells comprising the aforementioned tumor antigens, nucleic acids coding therefor, and/or vectors encompass further embodiments of the invention. These cells encompass any potential cell into which the aforementioned tumor antigen, nucleic acid, and/or vector might be introduced and/or transfected and/or infected (for example, bacteria, COS cells, Vero cells, chick embryo fibroblasts, tumor cells, antigen presenting cells, dendritic cells, etc.). The choice of process for the introduction and/or transfection and/or infection into cells is dependant upon the intrinsic nature of the introduced agent (i.e. free DNA, plasmid, recombinant virus), as will be known to one skilled in the art (for example, as taught in *Current*

Protocols in Molecular Biology, F.M. Ausubel et al. (Eds.), John Wiley and Sons, Inc., N.Y., U.S.A. (1998), Chpt. 9; *Molecular Cloning: A Laboratory Manual (2nd Ed)*, J. Sambrook, E.F. Fritsch and T Maniatis (Eds.), Cold Spring Harbor Laboratory Press, N.Y., U.S.A. (1989), Chpts. 1, 2, 3 and 16).

- 5 Further embodiments of the invention encompass vaccines comprising the tumor antigens and/or nucleic acids coding therefor and/or vectors and/or cells previously described.

The vaccine of the invention comprising the tumor antigen may be a multivalent vaccine and additionally contain several peptides, epitopes or
10 fragments of a particular tumor antigen or contain peptides related to other tumor antigens and/or infectious agents in a prophylactically or therapeutically effective manner. Multivalent vaccines against cancers may contain a number of individual TAA's, or immunogenic fragments thereof, alone or in combinations which are effective to modulate an immune
15 response to cancer.

A vaccine of the invention may contain a nucleic acid molecule encoding a tumor antigen of the invention. Such vaccines are referred to as nucleic acid vaccines but are also termed genetic vaccines, polynucleotide vaccines or DNA vaccines, all of which are within the scope of the present
20 invention. In such an embodiment, the tumor antigen is produced *in vivo* in the host animal. Additional embodiments if the invention encompass vectors (i.e. bacteria, recombinant viruses) comprising the aforementioned nucleic acids.

The present invention also contemplates mixtures of the tumor
25 antigens, nucleic acids coding therefor, vectors comprising said nucleic acids, cells and/or vaccines comprising the aforementioned, and at least one member selected from the group consisting of cytokines, lymphokines, immunostimulatory molecules, and nucleic acids coding therefor. Additional embodiments of this invention further encompass
30 pharmaceutical compositions comprising the aforementioned tumor antigens, nucleic acids coding therefor, vectors, cells, vaccines or mixtures for administration to subjects in a biologically compatible form suitable for

administration *in vivo*. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the substance to be administered in which any toxic effects are outweighed by the therapeutic effects. Administration of a therapeutically active amount of the pharmaceutical compositions of the present invention, or an "effective amount", is defined as an amount effective at dosages and for periods of time, necessary to achieve the desired result of eliciting an immune response in an animal. A therapeutically effective amount of a substance may vary according to factors such as the disease state/health, age, sex, and weight of the recipient, and the inherent ability of the particular tumor antigen, nucleic acid coding therefor, vector, cell, or vaccine to elicit a desired immune response. Dosage regima may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily, or at periodic intervals, and/or the dose may be proportionally reduced as indicated by the exigencies of circumstances.

The pharmaceutical compositions described herein can be prepared by *per se* known methods for the preparation of pharmaceutically acceptable compositions which can be administered to animals such that an effective quantity of the active substance (i.e. tumor antigen, nucleic acid, recombinant virus, vaccine) is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in "Handbook of Pharmaceutical Additives" (compiled by Michael and Irene Ash, Gower Publishing Limited, Aldershot, England (1995)). On this basis, the compositions include, albeit not exclusively, solutions of the substances in association with one or more pharmaceutically acceptable vehicles or diluents, and may be contained in buffered solutions with a suitable pH and/or be iso-osmotic with physiological fluids. In this regard, reference can be made to U.S. Patent No. 5,843,456. These compositions may further comprise an adjuvant (as described below).

Further embodiments of the invention encompass methods of inhibiting a tumor antigen expressing cancer cell in a patient comprising administering to said patient an effective amount of a tumor antigen, nucleic

acid coding therefore, vector, cell, or vaccine of the invention. Patients with solid tumors expressing tumor antigens include (but are not limited to) those suffering from colon cancer, lung cancer, pancreas cancer, endometrial cancer, breast cancer, thyroid cancer, melanoma, oral cancer, 5 laryngeal cancer, seminoma, hepatocellular cancer, bile duct cancer, squamous cell carcinoma, and prostate cancer. As such, methods of treating patients with cancer *per se* encompassing the aforementioned methods of inducing an immune response and/or inhibiting a tumor antigen expressing cell are contemplated aspects/embodiments of the invention.

10 As mentioned previously, an animal may be immunized with a tumor antigen, nucleic acid coding therefore, vector, cell or vaccine of the invention by administering the aforementioned to a lymphatic site. The administration can be achieved in a single dose or repeated at intervals. The appropriate dosage is dependant on various parameters understood by the skilled 15 artisans, such as the immunogen itself (i.e. polypeptide vs. nucleic acid (and more specifically type thereof)), the route of administration and the condition of the animal to be vaccinated (weight, age and the like).

As previously noted, nucleic acids (in particular plasmids and/or free/naked DNA and/or RNA coding for the tumor antigen of the invention) 20 can be administered to an animal for purposes of inducing/eliciting an immune response (for example, US Patent No. 5589466; McDonnell and Askari, *NEJM* 334:42-45 (1996); Kowalczyk and Ertl, *Cell Mol. Life Sci.* 55:751-770 (1999)). Typically, this nucleic acid is a form that is unable to replicate in the target animal's cell and unable to integrate in said animal's 25 genome. The DNA/RNA molecule encoding the tumor antigen is also typically placed under the control of a promoter suitable for expression in the animal's cell. The promoter can function ubiquitously or tissue-specifically. Examples of non-tissue specific promoters include the early Cytomegalovirus (CMV) promoter (described in U.S. Patent No. 4,168,062) 30 and the Rous Sarcoma Virus promoter. The desmin promoter is tissue-specific and drives expression in muscle cells. More generally, useful vectors have been described (i.e., WO 94/21797).

For administration of nucleic acids coding for a tumor antigen, said nucleic acid can encode a precursor or mature form of the polypeptide/protein. When it encodes a precursor form, the precursor form can be homologous or heterologous. In the latter case, a eucaryotic leader sequence can be used, such as the leader sequence of the tissue-type plasminogen factor (tPA).⁵

For use as an immunogen, a nucleic acid of the invention can be formulated according to various methods known to a skilled artisan. First, a nucleic acid can be used in a naked/free form, free of any delivery vehicles (such as anionic liposomes, cationic lipids, microparticles, (e.g., gold microparticles), precipitating agents (e.g., calcium phosphate) or any other transfection-facilitating agent. In this case the nucleic acid can be simply diluted in a physiologically acceptable solution (such as sterile saline or sterile buffered saline) with or without a carrier. When present, the carrier preferably is isotonic, hypotonic, or weakly hypertonic, and has a relatively low ionic strength (such as provided by a sucrose solution (e.g., a solution containing 20% sucrose)).¹⁰

¹⁵

Alternatively, a nucleic acid can be associated with agents that assist in cellular uptake. It can be, i.e., (i) complemented with a chemical agent that modifies the cellular permeability (such as bupivacaine; see, for example, WO 94/16737), (ii) encapsulated into liposomes, or (iii) associated with cationic lipids or silica, gold, or tungsten microparticles.²⁰

Cationic lipids are well known in the art and are commonly used for gene delivery. Such lipids include Lipofectin (also known as DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), DOTAP (1,2-bis(oleylloxy)-3-(trimethylammonio) propane), DDAB (dimethyldioctadecylammonium bromide), DOGS (dioctadecylamidoglycyl spermine) and cholesterol derivatives such as DC-Chol (3 beta-(N-(N',N'-dimethylaminomethane)-carbamoyl) cholesterol). A description of these cationic lipids can be found in EP 187702, WO 90/11092, U.S. Patent No. 5283185,²⁵ WO 91/15501, WO 95/26356, and U.S. Patent No. 5527928. Cationic lipids for gene delivery are preferably used in association with a neutral lipid such

as DOPE (dioleyl phosphatidylethanolamine) as, for example, described in WO 90/11092.

Other transfection-facilitating compounds can be added to a formulation containing cationic liposomes. A number of them are described 5 in, for example, WO 93/18759, WO 93/19768, WO 94/25608, and WO 95/2397. They include, for example, spermine derivatives useful for facilitating the transport of DNA through the nuclear membrane (see, for example, WO 93/18759) and membrane-permeabilizing compounds such as GALA, Gramicidine S, and cationic bile salts (see, for example, WO 10 93/19768).

Gold or tungsten microparticles can also be used for nucleic acid delivery (as described in WO 91/359 and WO 93/17706). In this case, the microparticle-coated polynucleotides can be injected via intradermal or intraepidermal routes using a needleless injection device ("gene gun"; such 15 as those described, for example, in U.S. Patent No. 4,945,050, U.S. Patent No. 5,015,580, and WO 94/24263).

Anionic and neutral liposomes are also well-known in the art (see, for example, *Liposomes: A Practical Approach*, RPC New Ed, IRL Press (1990), for a detailed description of methods for making liposomes) and are useful 20 for delivering a large range of products, including nucleic acids.

Particular embodiments of the aforementioned methods (i.e. to induce/elicit immune responses) encompass prime-boost protocols for the administration of immunogens of the invention. More specifically, these protocols encompass (but are not limited to) a "priming" step with a 25 particular/distinct form of immunogen (i.e. nucleic acid (for example, plasmid, bacterial/viral/free or naked)) coding for tumor antigen, or vector (i.e. recombinant virus, bacteria) comprising said nucleic acid) followed by at least one "boosting" step encompassing the administration of an alternate (i.e. distinct from that used to "prime") form of the tumor antigen 30 (i.e. protein or fragment thereof (for example, epitope/peptide), nucleic acid coding for the tumor antigen (or fragment thereof), or vector comprising said nucleic acid). Examples of "prime-boost" methodologies are known to

those skilled in the art (as taught, for example, in PCT published applications WO 98/58956, WO 98/56919, WO 97/39771). One advantage of said protocols is the potential to circumvent the problem of generating neutralizing immune responses to vectors *per se* (i.e. recombinant viruses) 5 wherein is inserted/incorporated nucleic acids encoding the immunogen or fragments thereof (see for example, R.M. Conry et al (2000) *Clin. Cancer Res.* 6:34-41).

As is well known to those of ordinary skill in the art, the ability of an immunogen to induce/elicit an immune response can be improved if, 10 regardless of administration formulation (i.e. recombinant virus, nucleic acid, polypeptide), said immunogen is co-administered with an adjuvant. Adjuvants are described and discussed in "Vaccine Design-the Subunit and Adjuvant Approach" (edited by Powell and Newman, Plenum Press, New York, U.S.A., pp. 61-79 and 141-228 (1995)). Adjuvants typically enhance the 15 immunogenicity of an immunogen but are not necessarily immunogenic in and of themselves. Adjuvants may act by retaining the immunogen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of immunizing agent to cells of the immune system. Adjuvants can also attract cells of the immune system to an immunogen 20 depot and stimulate such cells to elicit immune responses. As such, embodiments of this invention encompass compositions further comprising adjuvants.

Desirable characteristics of ideal adjuvants include:

- 1) lack of toxicity;
- 2) ability to stimulate a long-lasting immune response;
- 3) simplicity of manufacture and stability in long-term storage;
- 4) ability to elicit both cellular and humoral responses to antigens administered by various routes, if required;
- 5) synergy with other adjuvants;
- 30 6) capability of selectively interacting with populations of antigen presenting cells (APC);

- 7) ability to specifically elicit appropriate TH1 or TH2 cell-specific immune responses; and
- 8) ability to selectively increase appropriate antibody isotype levels (for example, IgA) against antigens/immunogens.

5 However, many adjuvants are toxic and can cause undesirable side effects, thus making them unsuitable for use in humans and many animals. For example, some adjuvants may induce granulomas, acute and chronic inflammations (i.e. Freund's complete adjuvant (FCA)), cytotoxicity (i.e. saponins and pluronic polymers) and pyrogenicity, arthritis and anterior 10 uveitis (i.e. muramyl dipeptide (MDP) and lipopolysaccharide (LPS)). Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in increasing antibody responses to diphtheria and tetanus toxoids is well established.

15 Notwithstanding, it does have limitations. For example, alum is ineffective for influenza vaccination and inconsistently elicits a cell mediated immune response with other immunogens. The antibodies elicited by alum-adjuvanted antigens are mainly of the IgG1 isotype in the mouse, which may not be optimal for protection in vaccination contexts.

20 Adjuvants may be characterized as "intrinsic" or "extrinsic". Intrinsic adjuvants (such as lipopolysaccharides) are integral and normal components of agents which in themselves are used as vaccines (i.e. killed or attenuated bacteria). Extrinsic adjuvants are typically nonintegral immunomodulators generally linked to antigens in a noncovalent manner,

25 and are formulated to enhance the host immune response

In embodiments of the invention, adjuvants can be at least one member chosen from the group consisting of cytokines, lymphokines, and co-stimulatory molecules. Examples include (but are not limited to)

interleukin 2, interleukin 12, interleukin 6, interferon gamma, tumor necrosis factor alpha, GM-CSF, B7.1, B7.2, ICAM-1, LFA-3, and CD72. Particular embodiments specifically encompass the use of GM-CSF as an adjuvant (as taught, for example, in US Patent Nos. 5679356, 5904920, 5637483, 5 5759535, 5254534, European Patent Application EP 211684, and published PCT document WO 97/28816 - all of which are herein incorporated by reference).

A variety of potent extrinsic adjuvants have been described. These include (but are not limited to) saponins complexed to membrane protein 10 antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria and mineral oil, Freund's complete adjuvant, bacterial products such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

The use of saponins *per se* as adjuvants is also well known 15 (Lacaille-Dubois, M. and Wagner, H. (1996) *Phytomedicine* 2:363). For example, Quil A (derived from the bark of the South American tree Quillaja Saponaria Molina) and fractions thereof has been extensively described (i.e. U.S. Patent No. 5057540; Kensil, C.R. (1996) *Crit Rev Ther Drug Carrier Syst.* 12:1; and European Patent EP 362279). The haemolytic saponins 20 QS21 and QS17 (HPLC purified fractions of Quil A) have been described as potent systemic adjuvants (U.S. Patent No. 5057540; European Patent EP 362279). Also described in these references is the use of QS7 (a non-haemolytic fraction of Quil-A) which acts as a potent adjuvant for systemic vaccines. Use of QS21 is further described in Kensil et al. ((1991) *J. 25 Immunol.* 146:431). Combinations of QS21 and polysorbate or cyclodextrin are also known (WO 9910008). Particulate adjuvant systems comprising fractions of Quil A (such as QS21 and QS7) are described in WO 9633739 and WO 9611711

Another preferred adjuvant/immunostimulant is an immunostimulatory oligonucleotide containing unmethylated CpG dinucleotides ("CpG"). CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. CpG is known in the art as being an adjuvant when administered by both systemic and mucosal routes (WO 9602555; European Patent EP 468520; Davies et al (1998) *J. Immunol.* 160:87; McCluskie and Davis (1998) *J. Immunol.* 161:4463). In a number of studies, synthetic oligonucleotides derived from BCG gene sequences have also been shown to be capable of inducing immunostimulatory effects (both in vitro and in vivo; Krieg, (1995) *Nature* 374:546). Detailed analyses of immunostimulatory oligonucleotide sequences has demonstrated that the CG motif must be in a certain sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA. (For example, the immunostimulatory sequence is often: purine, purine, C, G, pyrimidine, pyrimidine, wherein the CG motif is not methylated; however other unmethylated CpG sequences are known to be immunostimulatory and as such may also be used in the present invention.) As will be evident to one of normal skill in the art, said CG motifs/sequences can be incorporated into nucleic acids of the invention *per se*, or reside on distinct nucleic acids.

A variety of other adjuvants are taught in the art, and as such are encompassed by embodiments of this invention. U.S. Patent No. 4,855,283 granted to Lockhoff et al. (incorporated herein by reference) teaches glycolipid analogues and their use as adjuvants. These include N-glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immuno-modulators or adjuvants. Furthermore, Lockhoff et al. ((1991) *Chem. Int. Ed. Engl.* 30:1611) have reported that N-glycolipid analogs displaying structural similarities to the naturally-occurring glycolipids (such as

glycophospholipids and glycoglycerolipids) are also capable of eliciting strong immune responses in both herpes simplex virus vaccine and pseudorabies virus vaccine.

U.S. Patent No. 4,258,029 granted to Moloney (incorporated herein by reference) teaches that octadecyl tyrosine hydrochloride (OTH) functions as an adjuvant when complexed with tetanus toxoid and formalin inactivated type I, II and III poliomyelitis virus vaccine. Nixon-George et al. ((1990) *J. Immunol.* 14:4798) have also reported that octadecyl esters of aromatic amino acids complexed with a recombinant hepatitis B surface antigen enhanced the host immune responses against hepatitis B virus.

Adjuvant compounds may also be chosen from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative. Adjuvant compounds are the polymers of acrylic or methacrylic acid which are cross-linked, especially with polyalkenyl ethers of sugars or polyalcohols. These compounds are known by the term carbomer (Pharneuropa Vol. 8, No. 2, June 1996). Preferably, a solution of adjuvant according to the invention, especially of carbomer, is prepared in distilled water, preferably in the presence of sodium chloride, the solution obtained being at acidic pH. This stock solution is diluted by adding it to the desired quantity (for obtaining the desired final concentration), or a substantial part thereof, of water charged with NaCl, preferably physiological saline (NaCL 9 g/l) all at once in several portions with concomitant or subsequent neutralization (pH 7.3 to 7.4), preferably with NaOH. This solution at physiological pH will be used as it is for mixing with the immunizing agent; said mixture being amenable to storage in the freeze-dried, liquid or frozen form.

Persons skilled in the art can also refer to U.S. Patent No. 2,909,462 (incorporated herein by reference) which describes adjuvants

encompassing acrylic polymers cross-linked with a polyhydroxylated compound having at least 3 hydroxyl groups (preferably not more than 8), the hydrogen atoms of the at least three hydroxyls being replaced by unsaturated aliphatic radicals having at least 2 carbon atoms. The preferred radicals are those containing from 2 to 4 carbon atoms (e.g. vinyls, allyls and other ethylenically unsaturated groups). The unsaturated radicals may themselves contain other substituents, such as methyl. The products sold under the name Carbopol (BF Goodrich, Ohio, USA) are particularly appropriate. They are cross-linked with allyl sucrose or with allyl pentaerythritol. Among them, there may be mentioned Carbopol (for example, 974P, 934P and 971P). Among the copolymers of maleic anhydride and alkenyl derivative, the copolymers EMA (Monsanto; which are copolymers of maleic anhydride and ethylene, linear or cross-linked, (for example cross-linked with divinyl ether)) are preferred. Reference may be made to J. Fields et al. ((1960) *Nature* 186: 778) for a further description of these chemicals (incorporated (herein by reference)).

In further aspects of this invention, adjuvants useful for parenteral administration of immunizing agent include aluminum compounds (such as aluminum hydroxide, aluminum phosphate, and aluminum hydroxy phosphate; but might also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes). The antigen can be precipitated with, or adsorbed onto, the aluminum compound according to standard protocols well known to those skilled in the art.

Other adjuvants encompassed by embodiments of this invention include lipid A (in particular 3-de-O-acylated monophosphoryl lipid A (3D-MPL). 3D-MPL is a well known adjuvant manufactured by Ribi

Immunochem, Montana. It is often supplied chemically as a mixture of 3-de-O-acylated monophosphoryl lipid A with 4, 5, or 6 acylated chains. It can be prepared by the methods taught in GB 2122204B. A preferred form of 3D-MPL is in the form of a particulate formulation having a particle size less than 0.2 μm in diameter (European Patent EP 689454).

Adjuvants for mucosal immunization may include bacterial toxins (e.g., the cholera toxin (CT), the *E. coli* heat-labile toxin (LT), the *Clostridium difficile* toxin A and the pertussis toxin (PT), or combinations, subunits, toxoids, or mutants thereof). For example, a purified preparation of native cholera toxin subunit B (CTB) can be of use. Fragments, homologs, derivatives, and fusion to any of these toxins are also suitable, provided that they retain adjuvant activity. A mutant having reduced toxicity may be used. Mutants have been described (e.g., in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/6627 (Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PT mutant)). Additional LT mutants include, for example Ser-63-Lys, Ala-69-Gly, Glu-110-Asp, and Glu-112-Asp mutants. Other adjuvants (such as a bacterial monophosphoryl lipid A (MPLA)) of various sources (e.g., *E. coli*, *Salmonella minnesota*, *Salmonella typhimurium*, or *Shigella flexneri*) can also be used in the mucosal administration of immunizing agents.

Adjuvants useful for both mucosal and parenteral immunization include polyphosphazene (for example, WO 95/2415), DC-chol (3 β -(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol (for example, U.S. Patent No 5,283,185 and WO 96/14831) and QS-21 (for example, WO 88/9336).

Adjuvants/immunostimulants as described herein may be formulated together with carriers, such as for example liposomes, oil in water emulsions, and/or metallic salts including aluminum salts (such as

aluminum hydroxide). For example, 3D-MPL may be formulated with aluminum hydroxide (as discussed in EP 689454) or oil in water emulsions (as discussed in WO 9517210); QS21 may be advantageously formulated with cholesterol containing liposomes (as discussed in WO 9633739), in oil 5 water emulsions (as discussed in WO 9517210) or alum (as discussed in WO 9815287). When formulated into vaccines, immunostimulatory oligonucleotides (i.e. CpGs) are generally administered in free solution together with free antigen (as discussed in WO 9602555; McCluskie and Davis (1998) *Supra*), covalently conjugated to an antigen (as discussed in 10 WO 9816247), or formulated with a carrier such as aluminum hydroxide or alum (as discussed in Davies et al. *Supra*; Brazolot-Millan et al (1998) *Proc. Natl. Acad. Sci.* 95:15553).

Combinations of adjuvants/immunostimulants are also within the scope of this invention. For example, a combination of a monophosphoryl 15 lipid A and a saponin derivative (as described in WO 9400153, WO 9517210, WO 9633739, WO 9856414, WO 9912565, WO 9911214) can be used, or more particularly the combination of QS21 and 3D-MPL (as described in WO 9400153). A combination of an immunostimulatory oligonucleotide and a saponin (such as QS21), or a combination of 20 monophosphoryl lipid A (preferably 3D-MPL) in combination with an aluminum salt also form a potent adjuvant for use in the present invention.

The following non-limiting example is illustrative of the present invention:

EXAMPLES

25 **Example 1**

This example compares the intranodal injection with subcutaneous injection of a representative tumor antigen (modified gp100).

Methods and Experimental Design

Test System

Cynomolgus monkeys (*Macaca fascicularis*) purpose bred animals.

Supplier: Siconbrec "Simian Conservation Breeding & Research Center

5 Inc.", Fema Building, 44 Gil Puyat Avenue Makati, Metro Manila, Philippines.

Number of animals in the study: 12 (6 males and 6 females).

Age at initiation of treatment: 26 to 38 months.

▪ Body weight range at initiation of treatment (day -1)

▪ males: 1.73 to 2.34 kg

10 ▪ females: 1.71 to 2.65 kg.

Animal Husbandry

▪ Housing: one air-conditioned room;

▪ temperature: 19 to 25°C (target range),

▪ relative humidity: >40%

15 ▪ air changes: minimum 8 air changes per hour,

▪ lighting cycle: 12 hours light (artificial)/12 hours dark.

▪ Caging: animals were housed singly in stainless steel mesh cages
(approximately 540 x 810 x 760 mm).

▪ Diet: expanded complete commercial primate diet (Mazuri diet, Special

20 Diet Services Ltd., Witham, Essex, CM8, 3AD, Great Britain) analyzed for
chemical and bacterial contaminants.

Quantity distributed: 100g diet/animal/day.

In addition, animals received fruit daily (apple or banana)

Animals were fasted for at least 16 hours before blood sampling for clinical

25 laboratory investigations and before necropsy.

▪ Water: drinking water *ad libitum* (via bottles)

▪ Contaminants: no known contaminants were present in diet or water at
levels which might have interfered with achieving the objective of the study.

Pre-Treatment Procedures

- Animal health procedure: all animals received a clinical examination for ill-health on arrival and a veterinary clinical examination during the acclimatization period.
- 5 ▪ Acclimatization period: at least 3 weeks between animal arrival and start of treatment.

Experimental Design

- Allocation to treatment groups was performed during the acclimatization period using a random allocation procedure based on body weight classes.
- 10 ▪ Animals were assigned to the treatment groups shown in Table 1. The dose levels administered were shown in Table 2.

Administration of the Test/Control Articles

Group 1 and 2 Animals

- Method of administration: injection in the left inguinal lymph node.
- 15 Animals were lightly anaesthetized before each administration by an intramuscular injection of ketmine hydrochloride (Imalgene® 500 - Merial, Lyon, France). The same lymph node was injected on each occasion (left side). Each injection was followed by a local disinfection with iodine (Vétédine® - Vétoquinol, Lure, France).

Group 3

- Route: subcutaneous.
- Method of administration: bolus injection using a sterile syringe and needle introduced subcutaneously. Four injection sites were used followed by a local disinfection with iodine (Vétédine® - Vétoquinol, Lure, France).
- 25 Animals were also lightly anaesthetized before each administration by an intramuscular injection of ketamine hydrochloride (Imalgene® 500 - Merial, Lyon, France) in order to be under the same conditions as groups 1 and 2 animals.

Four injection sites in the dorsal cervical/interscapular regions were used as shown in Table 3.

▪ **ELISPOT Analysis**

An ELISPOT assay was used in order to assess the cell mediated immune response generated in the monkeys in the various treatment groups. In particular, an ELISPOT IFN γ assay was used in order to measure IFN γ production from T lymphocytes obtained from the monkeys in response to gp100 antigens.

10 **Materials and Methods**

Plates: MILLIPORE Multiscreen HA plate / MAHA S45.10 (96 wells).

Capture antibodies: MABTECH monoclonal anti-IFN γ antibodies/G-Z4 1 mg/mL.

Detection antibodies: MABTECH monoclonal anti-IFN γ antibodies/7-B6-1-15 biotin 1 mg/mL.

Enzyme: SIGMA, Extravidin-PA conjugate/E2636

Substrate: BIORAD, NBT/BCIP - Alkaline phosphatase conjugate substrate kit/ref: 170-64 32.

Coating

20 Place 100 μ L per well of capture antibodies at 1 μ g/mL diluted at 1/1000 in carbonate bicarbonate buffer 0.1M pH 9.6 into the multiwell plate. Incubate overnight at 4°C. Wash 4 times in 1X PBS.

Saturation

Place 200 μ L per well of RPMI supplemented with 10% FCS, non essential 25 amino acids, pyruvate, Hepes buffer and Peni-Strepto. Incubate 2 hours at 37°C.

Test

Cells from the immunized animals are tested against (a) medium alone; (b) pooled peptides at a concentration of 1 mg/mL; and (c) a non specific

stimulus (PMA-Iono) The pooled peptides used in this Example to stimulate IFN- γ production were derived from gp100 and are illustrated in Tables 4 to 7. The final volume of each sample is 200 μ L. Incubate 20 hours at 37°C.

- 5 Wash 4 times in 1X PBS and 0.05% Tween 20.

Detection

Place 100 μ L per well of detection antibodies at 1 μ g/mL diluted in 1/1000 1X PBS, 1% BSA and 0.05% Tween 20. Incubate 2 hours at room temperature. Wash 4 times in 1X PBS and 0.05% Tween 20.

- 10 **Reaction**

Place 100 μ L per well of Extravidin-PA conjugate diluted 1/6000 in 1X PBS, 1% BSA and 0.05% Tween 20. Incubate 45 minutes at room temperature.

Wash 4 times in 1X PBS and 0.05% Tween 20.

Substrate Addition

- 15 Place 100 μ L per well of substrate previously prepared. For example, for 1 plate, prepare: 9.6 mL of distilled water, 0.4 mL of 25X buffer, 0.1 mL of solution A (NBT) and 0.1 mL of solution B (BCIP). Incubate 30-45 minutes at room temperature. Wash in distilled water. Dry and transfer to a plastic film. The number of spots are counted using a Zeiss image analyzer. Each
20 spot corresponds to an individual IFN- γ secreting T cell.

Results

The animals that tested positive on the ELISPOT analysis are shown in Figures 1-4. Overall, the results demonstrate that of the animals tested, 25 out of 2 (i.e. 100%) of the animals that received the intranodal administration of the gp100 antigen, and 2 out of 4 (i.e. 50%) of the animals that received the subcutaneous administration of the gp100 antigen had a positive cell mediated immune response.

ELISA Analysis

The ELISA was performed utilizing standard methodology known in the art. Briefly, the human gp100 ("hgp100"; produced in Baculovirus) was diluted in 5 coating buffer (carbonate-bicarbonate, pH9.6) and added to 96 wells at 0.5ug/well. Plates were placed at 4°C overnight. Plates were then washed and blocking buffer (phosphate buffered saline/0.5% Tween 20/1.0% BSA, pH7.2) was added for 2 hours at 37°C. The plates were then washed and the sera was diluted in dilution buffer (phosphate buffered saline/0.5 % 10 Tween 20/ 0.1 BSA, pH7.2). For this study, monkey sera was diluted to 1:800 and "7" serial 3 fold dilutions were done for each sample tested. The human sera controls were diluted to 1:50 in dilution buffer and "7" serial 2 fold dilutions were performed. Each dilution was done in duplicate. The plates were incubated a further 2 hours at 37°C. The plates were washed 15 and the horse radish peroxidase (HRP)-conjugated anti-human secondary antibody (anti-human Ig whole antibody from sheep (Amersham Life Science, NA933)) diluted 1:100 in dilution buffer was added to the wells and incubated for 1 hour at 37°C. The plates were washed and OPD (o-phenylenediamine dihydrochloride) substrate with H₂O₂ in substrate buffer 20 (50mM phosphate/25mM citrate, pH 7.2) was added to the wells. For a kinetics ELISA, the plate was read repeatedly (2 minute intervals for 15 minutes) unstopped (without "stop" buffer). Plates were read at 450nm.

Results

25 The results of the above experiment are presented in Table 8 and in Figure 5. The animals of group 2 received intranodal injections of ALVAC(2)-gp100(mod) followed by boosts with the modified gp100 peptides 209(2M) and 290(9V); the animals in group 3 received a subcutaneous

injection of the ALVAC(2) construct followed by peptide boosts; the animals in group 1 received intranodal injections of saline as a control.

As can be seen from Figure 5, intranodal injection of the antigens induced a humoral response that was much greater than when the antigen
5 was injected subcutaneously.

In summary, the results of this Example demonstrate that intranodal injection of a tumor antigen induces both a humoral and cell mediated response that is much greater than when the tumor antigen is injected by the conventional subcutaneous route of administration.

10 While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the
15 appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

TABLE 1

| Group Number | Route of administration | Treatment days and compound administered | Number of Animals |
|--------------|-------------------------|--|-------------------|
| 1 | Intranodal | Saline (NaCl 0.9%): days 28, 42, 56 Then 70, 71, 72, 73, 74 Then 84, 85, 86, 87 and 88 | 4 |
| 2 | Intranodal | ALVAC(2) - gp100 mod days 28, 42, 56 *mgp100 peptides days 70, 71, 72, 73, 74 Then 84, 85, 86, 87 and 88 | 4 |
| 3 | Subcutaneous | Saline (NaCl 0.9%): day 1 ALVAC(2) - gp100 mod days 28, 42, 56 *mgp100 peptides: days 70 and 84 | 4 |

*209(2M)-IMDQVRFSY, 290(9V) YLEPGPVTV

- 5 • Group 1 animals (control) received the control article (saline for injection (NaCl 0.9%)).
 • Group 3 animals received the control article (saline for injection (NaCl 0.9%)) on day 1 only

36
TABLE 2

| Group Number | Dose level | Dose volume (ml/administration) |
|--------------|---|---------------------------------|
| 1 | Saline (NaCl 0.9%): 0 | 0.250 |
| 2 | Dose: $0.25 \times 10^{7.4}$ CCID 50 ALVAC (2) - gp100 mod: $0.25 \times 10^{7.4}$ CCID50 Dose: 200 µg (Total) of peptides IMDQVPFSY (209(2M)) and YLEPGPVTV (290(9V)) (100µg each) | 0.250 0.2 |
| 3 | Saline (NaCl 0.9%) ALVAC(2) - gp100 mod: $0.25 \times 10^{7.4}$ CCID 50 Dose: 200 µg (Total) of peptides IMDQVPFSY (209(2M)) and YLEPGPVTV (290(9V)) (100µg each) | 0.250 0.250 0.2 |

37
TABLE 3

| Days | Sites used |
|----------|-------------|
| 1 and 28 | lower left |
| 42 | upper left |
| 56 | upper right |
| 70 | lower left |
| 84 | lower right |

TABLE 4

Peptide Pool #1

| Peptide | Sequence | SEQ ID.NO. |
|---------|-------------------|--------------|
| 1329 | HLAVIGALLAVGATK | SEQ.ID.NO.3 |
| 1330 | GALLAVGATKVPRNQ | SEQ.ID.NO.4 |
| 1331 | VGATKVPRNQDWLGV | SEQ.ID.NO.5 |
| 1332 | VPRNQDWLGVSRLQR | SEQ.ID.NO.6 |
| 1333 | DWLGVSRQLRTKAWN | SEQ.ID.NO.7 |
| 1334 | SRQLRTKAWNRQLYP | SEQ.ID.NO.8 |
| 1335 | TKAVERNQLYPEWTEA | SEQ.ID.NO.9 |
| 1336 | RQLYPEWTEAQRLDC | SEQ.ID.NO.10 |
| 1337 | EWTEAQRLDCWRGGQ | SEQ.ID.NO.11 |
| 1338 | QRLDCWRGGQVSLKV | SEQ.ID.NO.12 |
| 1339 | WRGGQVSLKVSNDGP | SEQ.ID.NO.13 |
| 1340 | VSLKVSNDGPTLIGA | SEQ.ID.NO.14 |
| 1344 | IALNFPGSQVKVLPDG | SEQ.ID.NO.15 |
| 1345 | PGSQVKVLPDGQVIVWV | SEQ.ID.NO.16 |
| 1346 | VLPDGQVIVVNNTII | SEQ.ID.NO.17 |
| 1347 | QVIWVNNTIINGSQV | SEQ.ID.NO.18 |
| 1348 | NNTIINGSQVWGGQP | SEQ.ID.NO.19 |
| 1349 | NGSQVWGGQPVYPQE | SEQ.ID.NO.20 |
| 1350 | WGGQPVYPQETDDAC | SEQ.ID.NO.21 |
| 1351 | VYPQETDDACIFPDG | SEQ.ID.NO.22 |
| 1352 | TDDACIFPDGGPCPS | SEQ.ID.NO.23 |
| 1353 | IFPDGGPCPSGSWSQ | SEQ.ID.NO.24 |
| 1355 | GSWSQKRSFVYVWKT | SEQ.ID.NO.25 |
| 1356 | KRSFVYVWKTWGQYW | SEQ.ID.NO.26 |
| 1357 | YVWKTWGQYWQVLGG | SEQ.ID.NO.27 |
| 1358 | WGQYWQVLGGPVSGL | SEQ.ID.NO.28 |
| 1359 | QVLGGPVSGLSIGTG | SEQ.ID.NO.29 |

39
TABLE 5

Peptide Pool #2

| Peptide | Sequence | SEQ.ID.NO. |
|---------|-----------------|--------------|
| 1360 | PVSGLSIGTGRAMLG | SEQ.ID.NO.30 |
| 1361 | SIGTGRAMLGTHTME | SEQ.ID.NO.31 |
| 1362 | RAMLGHTMEVTVYH | SEQ.ID.NO.32 |
| 1363 | THTMEVTVYHRRGSR | SEQ.ID.NO.33 |
| 1364 | VTYHRRGSRSYVPI | SEQ.ID.NO.34 |
| 1365 | RRGSRSYVPLAHSSS | SEQ.ID.NO.35 |
| 1366 | SYVPLAHSSSAFTIT | SEQ.ID.NO.36 |
| 1368 | AFTITDQVPFSVSVS | SEQ.ID.NO.37 |
| 1369 | DQVPFSVSQSQLRAL | SEQ.ID.NO.38 |
| 1370 | SVSVSQLRALDGGNK | SEQ.ID.NO.39 |
| 1372 | DGGNKHFLRNQPLTF | SEQ.ID.NO.40 |
| 1373 | HFLRNQPLTFALQLH | SEQ.ID.NO.41 |
| 1374 | QPLTFALQLHDPSGY | SEQ.ID.NO.42 |
| 1375 | ALQLHDPSGYLAEAD | SEQ.ID.NO.43 |
| 1379 | DFGDSSCTLISRALV | SEQ.ID.NO.44 |
| 1380 | STGLISRALVVTHTY | SEQ.ID.NO.45 |
| 1381 | SRALVVTHTYLEPGP | SEQ.ID.NO.46 |
| 1382 | VTHTYLEPGPVTAQV | SEQ.ID.NO.47 |
| 1383 | LEPGPVTAQVVLQAA | SEQ.ID.NO.48 |
| 1384 | VTAQVVLQAAIPLTS | SEQ.ID.NO.49 |
| 1385 | VLQAAIPLTSCGSSP | SEQ.ID.NO.50 |
| 1386 | IPLTSCGSSPVPGTT | SEQ.ID.NO.51 |
| 1388 | VPGTTDGHRTAEAP | SEQ.ID.NO.52 |
| 1389 | DGHRTAEPNTTAG | SEQ.ID.NO.53 |
| 1390 | TAEAPNTTAGQVPTT | SEQ.ID.NO.54 |
| 1392 | QVPTTEVVGTTPGQA | SEQ.ID.NO.55 |
| 1393 | EVVGTTPGQAPTAEP | SEQ.ID.NO.56 |

40
TABLE 6

Peptide Pool #3

| Peptide | Sequence | SEQ.ID.NO. |
|---------|------------------|--------------|
| 1394 | TPGQAPTAEPSTTTS | SEQ.ID.NO.57 |
| 1395 | PTAEPSTGTTSVQVPT | SEQ.ID.NO.58 |
| 1396 | SGTTSVQVPTTEVIS | SEQ.ID.NO.59 |
| 1397 | VQVPTTEVISTAPVQ | SEQ.ID.NO.60 |
| 1398 | TEVISTAPVQMPTAE | SEQ.ID.NO.61 |
| 1399 | TAPVQMPTAESTGMT | SEQ.ID.NO.62 |
| 1400 | MPTAESTGMTPEKVP | SEQ.ID.NO.63 |
| 1401 | STGMTPEKVPSEVM | SEQ.ID.NO.64 |
| 1402 | PEKVPVSEVMGTTLA | SEQ.ID.NO.65 |
| 1403 | VSEVMGTTLAEMSTP | SEQ.ID.NO.66 |
| 1404 | GTTLAEMSTPEATGM | SEQ.ID.NO.67 |
| 1405 | EMSTPEATGMTPAEV | SEQ.ID.NO.68 |
| 1408 | SIVVLSGTTAAQVTT | SEQ.ID.NO.69 |
| 1409 | SGTTAAQVTTTEWVE | SEQ.ID.NO.70 |
| 1410 | AQVTTTEWVETTARE | SEQ.ID.NO.71 |
| 1411 | TEWVETTARELPIPE | SEQ.ID.NO.72 |
| 1412 | TTARELPIPEPEGPD | SEQ.ID.NO.73 |
| 1413 | LPIPEPEGPDASSIM | SEQ.ID.NO.74 |
| 1414 | PEGPDASSIMSTESI | SEQ.ID.NO.75 |
| 1415 | ASSIMSTESITGSLG | SEQ.ID.NO.76 |
| 1416 | STESITGSLGPLLDG | SEQ.ID.NO.77 |
| 1417 | TGSLGPLLDGTATIR | SEQ.ID.NO.78 |
| 1418 | PLLDGTATLRLVKRQ | SEQ.ID.NO.79 |
| 1419 | TATLRLVKRQVPLDC | SEQ.ID.NO.80 |
| 1420 | LVKRQVPLDCVLYRY | SEQ.ID.NO.81 |
| 1421 | VPLDCVLYRYGSFSV | SEQ.ID.NO.82 |
| 1422 | VLYRYGSFSVILDIV | SEQ.ID.NO.83 |

Peptide Pool #4

| Peptide | Sequence | SEQ.ID.NO. |
|---------|------------------|---------------|
| 1424 | TLDIVQGIESAELQ | SEQ.ID.NO.84 |
| 1425 | QGIESAELQAVPMSG | SEQ.ID.NO.85 |
| 1426 | AELQAVPSGEGDCAF | SEQ.ID.NO.86 |
| 1427 | AVPSGEGDCAFELTVS | SEQ.ID.NO.87 |
| 1428 | EGDAFELTVSCQGGL | SEQ.ID.NO.88 |
| 1429 | ELTVSCQGGLPKEAC | SEQ.ID.NO.89 |
| 1430 | CQGGLPKEACMEISS | SEQ.ID.NO.90 |
| 1431 | PKEACMEISSLPGCQP | SEQ.ID.NO.91 |
| 1432 | MEISSLPGCQPPAQRL | SEQ.ID.NO.92 |
| 1434 | PAQRLLCOPVLPSPAC | SEQ.ID.NO.93 |
| 1435 | CQPVLPSPACOLVLH | SEQ.ID.NO.94 |
| 1436 | PSPACQLVLHQILKG | SEQ.ID.NO.95 |
| 1437 | QLVLHQILKQGSPTY | SEQ.ID.NO.96 |
| 1441 | LADTNSLAVVSTQLI | SEQ.ID.NO.97 |
| 1442 | SLAVVSTQLIMPQOE | SEQ.ID.NO.98 |
| 1443 | STQLIMPQOEAGLGQ | SEQ.ID.NO.99 |
| 1444 | MPGQEAGLGQVPLIV | SEQ.ID.NO.100 |
| 1445 | AGLGQVPLIVGILLV | SEQ.ID.NO.101 |
| 1448 | LMAVVVLASLIYRRRL | SEQ.ID.NO.102 |
| 1450 | YRRRLMKQDFSVPQL | SEQ.ID.NO.103 |
| 1451 | MKQDFSVPQLPHSSS | SEQ.ID.NO.104 |
| 1452 | SVPQLPHSSSHWLRL | SEQ.ID.NO.105 |
| 1453 | PHSSSSHWLRLPRIFC | SEQ.ID.NO.106 |
| 1454 | HWLRLPRIFCSCP1G | SEQ.ID.NO.107 |
| 1455 | PRIFCSCP1GENSPL | SEQ.ID.NO.108 |

TABLE 8

| Monkey # | DAY (mOD/min) | | | |
|----------|---------------|----|----|----|
| | 0 | 57 | 68 | 96 |
| 1 | 3 | 5 | 2 | 2 |
| 2 | 4 | 6 | 12 | 10 |
| 3 | 7 | 6 | 10 | 8 |
| 4 | 7 | 6 | 8 | 8 |
| 5 | 5 | 9 | 20 | 15 |
| 6 | 11 | 8 | 10 | 12 |
| 7 | 11 | 23 | 51 | 30 |
| 8 | 7 | 30 | 70 | 22 |
| 9 | 1 | 7 | 5 | 3 |
| 10 | 2 | 6 | 6 | 4 |
| 11 | 3 | 7 | 14 | 8 |
| 12 | 6 | 9 | 15 | 6 |

We claim:

1. A method for inducing an immune response in an animal to a tumor antigen comprising administering an effective amount of a tumor antigen or a nucleic acid sequence encoding a tumor antigen to a lymphatic site in the animal.
2. A method according to claim 1 wherein the tumor antigen is selected from the group consisting of CEA, gp100, the MAGE family of proteins, DAGE, GAGE, RAGE, NY-ESO 1, Melan-A/MART 1, TRP-1, TRP-2, tyrosinase, HER-2/neu, MUC-1, p53, KSA, PSA, PSMA, and fragments and modified versions thereof.
- 15 3. A method according to claim 1 wherein the lymphatic site is a lymph node.
4. A method according to claim 1 wherein the nucleic acid is selected from the group consisting of viral nucleic acid, bacterial DNA, plasmid 20 DNA, naked/free DNA, and RNA.
5. A method according to claim 4 wherein the viral nucleic acid is selected from the group consisting of adenoviral, alphaviral and poxviral nucleic acid.
- 25 6. A method according to claim 5 wherein the poxviral nucleic acid is selected from the group consisting of avipox, orthopox and suipox nucleic acid.
- 30 7. A method according to claim 5 wherein the poxviral nucleic acid is selected from the group consisting of vaccinia, fowl pox, canarypox and swinepox nucleic acid.

8. A method according to claim 5 wherein the poxviral nucleic acid is selected from the group consisting of MVA, NYVAC, TROVAC, and ALVAC nucleic acid.
- 5
9. A method according to claim 1 wherein the nucleic acid is contained in a vector.
10. A method according to claim 9 wherein the vector is a recombinant virus or bacteria.
11. A method according to claim 10 wherein the recombinant virus is selected from the group consisting of adenovirus, alphavirus and poxvirus.
- 15
12. A method according to claim 11 wherein the poxvirus is selected from the group consisting of avipox, orthopox and suipox.
13. A method according to claim 11 wherein the poxvirus is selected from the group consisting of vaccinia, fowlpox, canarypox and swinepox.
- 20
14. A method according to claim 11 wherein the poxvirus is selected from the group consisting of MVA, NYVAC, TROVAC, and ALVAC.
- 25 15. A method according to claim 1 wherein the nucleic acid is contained in a cell.
- 16 A method according to claim 1 wherein the tumor antigen or nucleic acid coding therefor is contained in a vaccine.
- 30
17. A method according to claim 1 wherein the tumor antigen is gp100, CEA or a fragment or modified version of gp100 or CEA..

18. A method according to claim 17 wherein the modified gp100 comprises the sequence IMDQVPPFSY (SEQ ID NO: 1) and/or YLEPGPVTV (SEQ ID NO:2).

5

19. A method according to claim 17 wherein the modified CEA comprises the sequence shown in Figure 8 (SEQ ID NO:112) and/or YLSGADLNL (SEQ ID NO:113).

10

ABSTRACT

5 An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen, nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid, or vaccines comprising the aforementioned to a lymphatic site.

Spots/1E6 Cells

FIGURE 1
Monkey #6 (Intranodal Administration)




FIGURE 2

Monkey #7 (Intranodal Administration)




FIGURE 3
Monkey # 11 (Subcutaneous Administration)




FIGURE 4
Monkey #10 (Subcutaneous Administration)




FIGURE 5




FIGURE 6

ATGG ATCTGGTGC TAAAAAGATGC CTTCTTCATT TGGCTGTGAT
AGGTGCTTG CTGGCTGTGG GGGCTACAAA AGTACCCAGA AACCAAGGACT GGCTTGGTGT
CTCAAGGCAA CTCAGAACCA AAGCCTGGAA CAGGCAGCTG TATCCAGAGT GGACAGAAC
CCAGACACTT GACTGCTGGA GAGGTGGTCA AGTGTCCCTC AAGGTCAGTA ATGATGGGCC
TACACTGATT GGTGCAAATG CCTCCTTCTC TATTGCTTG AACTTCCCTG GAAGCCAAA
GGTATTGCCA GATGGCAGG TTATCTGGGT CAACAATACC ATCATCAATG GGAGCCAGGT
GTGGCCAGGA CAGCCAGTGT ATCCCCAGGA AACTGACGAT GCCTGCATCT TCCCTGATGG
TGGACCTTGC CCATCTGGCT CTGGTCTCA AAAGAGAAC TTTGTTTATG TCTGGAAGAC
CTGGGGCCAA TACTGGCAAG TTCTAGGGGG CCCAGTGTCT GGGCTGAGCA TTGGGACAGG
CAGGGCAATG CTGGGCACAC ACACGATGGA AGTGAATGTC TACCATCGCC GGGGATCCCG
GAGCTATGTG CCTCTTGCTC ATTCCAGCTC AGCCTTCACC ATTATGGACC AGGTGCCTTT
CTCCGTGAGC GTGCCCCAGT TGCGGGCCTT GGATGGAGGG AACAAAGCACT TCCGTGAGAAA
TCAGCCCTCG ACCTTTGCC TCCAGCTCCA TGACCCCAGT GGCTATCTGG CTGAAGCTGA
CCTCTCCTAC ACCTGGGACT TTGGAGACAG TAGTGGAACCT CTGATCTCTC GGGCACTTGT
GGTCACTCAT ACTTACCTGG AGCCTGGCCC AGTCACTGTT CAGGTGGTCC TGCAGGCTGC
CATTCCCTCTC ACCTCCTGTG GCTCCCTCCCC AGTTCAGGC ACCACAGATG GGCACAGGCC
AACTGCAGAG GCCCCTAACCA CCACAGCTGG CCAAGTGCCT ACTACAGAAG TTGTGGGTAC
TACACCTGGT CAGGCGCCAA CTGCAGAGCC CTCTGGAAC ACATCTGTGC AGGTGCCAAC
CACTGAAGTC ATAAGCACTG CACCTGTGCA GATGCCAATC GCAAGAGAGCA CAGGTATGAC
ACCTGAGAAC AGGCCAGTT CAGAGGTCAAT GGGTACCAAC CTGGCAGAGAGA TGTCAACTCC
AGAGGCTACA GGTATGACAC CTGCAGAGGT ATCAATTGTG GTGCTTCTG GAACCAACAGC
TGCACAGGTA ACAACTACAG AGTGGGTGGA GACCACAGCT AGAGAGCTAC CTATCCCTGA
GCCTGAAGGT CCAGATGCCA GCTCAATCAT GTCTACGGAA AGTATTACAG GTTCCCTGGG
CCCCCTGCTG GATGGTACAG CCACCTTAAG GCTGGTGAAG AGACAAGTCC CCCTGGATTG
TGTCTGTAT CGATATGGTT CCTTTCCGT CACCCCTGGAC ATTGTCCAGG GTATTGAAAG
TGCCGAGATO CTGCAGGCTG TGCGTCCGG TGAGGGGGAT GCATTTGAGC TGACTGTGTC
CTGCCAAGGC GGGCTGCCA AGGAAGCCTG CATGGAGATC TCATCGCCAG GGTGCCAGCC
CCCTGCCAG CGGCTGTGCC AGCCTGTGCT ACCCAGCCCA GCCTGCCAGC TGGTTCTGCA
CCAGATACTG AAGGGTGGCT CGGGGACATA CTGCCCTCAAT GTGCTCTGG CTGATACCAA
CAGCCTGGCA GTGGTCAGCA CCCAGTTAT CATGCCCTGGT CAAGAAGCAG GCCTTGGGCA
GGTTCCGCTG ATCGTGGGCA TCTGCTGGT GTTGATGGCT GTGGTCCCTG CATCTCTGAT
ATATAGGCAGC AGACTTATGA AGCAAGACTT CTCCGTACCC CAGTTGCCAC ATAGCAGCAG
TCACTGGCTG CGTCTACCCC GCATCTCTG CTCTTGTCCC ATTGGTGAGA ACAGCCCCCT
CCTCAGTGGG CAGCAGGTCT GA

FIGURE 7

Met Asp Leu Val Leu Lys Arg Cys Leu Leu His Leu Ala Val Ile Gly
 1 5 10 15

Ala Leu Leu Ala Val Gly Ala Thr Lys Val Pro Arg Asn Gln Asp Trp
 20 25 30

Leu Gly Val Ser Arg Gln Leu Arg Thr Lys Ala Trp Asn Arg Gln Leu
 35 40 45

Tyr Pro Glu Trp Thr Glu Ala Gln Arg Leu Asp Cys Trp Arg Gly Gly
 50 55 60

Gln Val Ser Leu Lys Val Ser Asn Asp Gly Pro Thr Leu Ile Gly Ala
 65 70 75 80

Asn Ala Ser Phe Ser Ile Ala Leu Asn Phe Pro Gly Ser Gln Lys Val
 85 90 95

Leu Pro Asp Gly Gln Val Ile Trp Val Asn Asn Thr Ile Ile Asn Gly
 100 105 110

Ser Gln Val Trp Gly Gly Gln Pro Val Tyr Pro Gln Glu Thr Asp Asp
 115 120 125

Ala Cys Ile Phe Pro Asp Gly Gly Pro Cys Pro Ser Gly Ser Trp Ser
 130 135 140

Gln Lys Arg Ser Phe Val Tyr Val Trp Lys Thr Trp Gly Gln Tyr Trp
 145 150 155 160

Gln Val Leu Gly Gly Pro Val Ser Gly Leu Ser Ile Gly Thr Gly Arg
 165 170 175

Ala Met Leu Gly Thr His Thr Met Glu Val Thr Val Tyr His Arg Arg
 180 185 190

Gly Ser Arg Ser Tyr Val Pro Leu Ala His Ser Ser Ser Ala Phe Thr
 195 200 205

~~Met~~
 Ile ~~Asp~~ Gln Val Pro Phe Ser Val Ser Val Gln Leu Arg Ala
 210 215 220

Leu Asp Gly Gly Asn Lys His Phe Leu Arg Asn Gln Pro Leu Thr Phe
 225 230 235 240

Ala Leu Gln Leu His Asp Pro Ser Gly Tyr Leu Ala Glu Ala Asp Leu
 245 250 255

Ser Tyr Thr Trp Asp Phe Gly Asp Ser Ser Gly Thr Leu Ile Ser Arg
 260 265 270

~~Val~~
 Ala Leu Val Val Thr His Thr Tyr Leu Glu Pro Gly Pro Val Thr ~~Asp~~
 275 280 285

Gln Val Val Leu Gln Ala Ala Ile Pro Leu Thr Ser Cys Gly Ser Ser
 290 295 300

Pro Val Pro Gly Thr Thr Asp Gly His Arg Pro Thr Ala Glu Ala Pro
 305 310 315 320

Asn Thr Thr Ala Gly Gln Val Pro Thr Thr Glu Val Val Gly Thr Thr
 325 330 335

Pro Gly Gln Ala Pro Thr Ala Glu Pro Ser Gly Thr Thr Ser Val Gln
 340 345 350

Val Pro Thr Thr Glu Val Ile Ser Thr Ala Pro Val Gln Met Pro Thr
 355 360 365

FIGURE 7 (CONT'D)

Ala Glu Ser Thr Gly Met Thr Pro Glu Lys Val Pro Val Ser Glu Val
 370 375 380
 Met Gly Thr Thr Leu Ala Glu Met Ser Thr Pro Glu Ala Thr Gly Met
 385 390 395 400
 Thr Pro Ala Glu Val Ser Ile Val Val Leu Ser Gly Thr Thr Ala Ala
 405 410 415
 Gln Val Thr Thr Thr Glu Trp Val Glu Thr Thr Ala Arg Glu Leu Pro
 420 425 430
 Ile Pro Glu Pro Glu Gly Pro Asp Ala Ser Ser Ile Met Ser Thr Glu
 435 440 445
 Ser Ile Thr Gly Ser Leu Gly Pro Leu Leu Asp Gly Thr Ala Thr Leu
 450 455 460
 Arg Leu Val Lys Arg Gln Val Pro Leu Asp Cys Val Leu Tyr Arg Tyr
 465 470 475 480
 Gly Ser Phe Ser Val Thr Leu Asp Ile Val Gln Gly Ile Glu Ser Ala
 485 490 495
 Glu Ile Leu Gln Ala Val Pro Ser Gly Glu Gly Asp Ala Phe Glu Leu
 500 505 510
 Thr Val Ser Cys Gln Gly Gly Leu Pro Lys Glu Ala Cys Met Gln Ile
 515 520 525
 Ser Ser Pro Gly Cys Gln Pro Pro Ala Gln Arg Leu Cys Gln Pro Val
 530 535 540
 Leu Pro Ser Pro Ala Cys Gln Leu Val Leu His Gln Ile Leu Lys Gly
 545 550 555 560
 Gly Ser Gly Thr Tyr Cys Leu Asn Val Ser Leu Ala Asp Thr Asn Ser
 565 570 575
 Leu Ala Val Val Ser Thr Gln Leu Ile Met Pro Gly Gln Glu Ala Gly
 580 585 590
 Leu Gly Gln Val Pro Leu Ile Val Gly Ile Leu Ile Val Leu Met Ala
 595 600 605
 Val Val Leu Ala Ser Leu Ile Tyr Arg Arg Arg Leu Met Lys Gln Asp
 610 615 620
 Phe Ser Val Pro Gln Leu Pro His Ser Ser Ser His Trp Leu Arg Leu
 625 630 635 640
 Pro Arg Ile Phe Cys Ser Cys Pro Ile Gly Glu Asn Ser Pro Leu Leu
 645 650 655
 Ser Gly Gln Gln Val
 660

ATGGAGTCTCCCTCGGCCCTCCCCACAGATGGTCATCCCCTGGCAGAGGCTCTGCTC
 1 -----+-----+-----+-----+-----+-----+-----+ 60
 TACCTCAGAGGGAGCCGGGGAGGGGTGTCTACCACGTAGGGGACCGTCTCGAGGACGAG

a M E S P S A P P H R W C I P W Q R L L L -

ACAGCCTCACTTCTAACCTCTGGAACCGCCCCACACTGCCAAGCTCACTATTGAATCC
 61 -----+-----+-----+-----+-----+-----+-----+ 120
 TGTCGGAGTGAAGATTGAAAGACCTTGGCGGGTGGTGACGGTTGAGTGATAACTTAGG

a T A S L L T F W N P P T T A K L T I E S -

ACGCCGTTCAATGTCGCAGAGGGAGGGGTGCTTACTTGTCCACAATCTGCCAG
 121 -----+-----+-----+-----+-----+-----+-----+ 180
 TGCGGCAAGTTACAGCGTCTCCCTCCTCACGAAGATGAACAGGTGTTAGACGGGTC

a T P F N V A E G K E V L L L V H N L P Q -

CATCTTTGGCTACAGCTGGTACAAAGGTGAAAGAGTGATGGCAACCGTCAAATTATA
 181 -----+-----+-----+-----+-----+-----+-----+ 240
 GTAGAAAAACCGATGTCGACCATGTTCCACTTCTCACCTACCGTGGCAGTTAATAT

a H L F G Y S W Y K G E R V D G N R Q I I -

GGATATGTAATAGGAACCTAACAGCTACCCAGGGCCGCATACAGGGTCGAGAGATA
 241 -----+-----+-----+-----+-----+-----+-----+ 300
 CCTATACATTATCCTGAGTTGTTGATGGGTCCCGGGCGTATGTCACCAAGCTCTAT

a G Y V I G T Q Q A T P G P A Y S G R E I -

ATATACCCAATGCATCCCTGCTGATCCAGAACATCATCCAGAACATGACACAGGATTCTAC
 301 -----+-----+-----+-----+-----+-----+-----+ 360
 TATATGGGTTACGTAGGGACACTAGGTCTTGTAGTAGGTCTTACTGTGTCCTAACGATG

a I Y P N A S L L I Q N I I Q N D T G F Y -

ACCCTACACGTATAAAGTCAGATCTTGTGAATGAAGAACAACTGGCCAGTTCCGGTA
 361 -----+-----+-----+-----+-----+-----+-----+ 420
 TGGGATGTGCAGTATTCAGTCTAGAACACTTACTTCTCGTTGACCGGTCAAGGCCAT

a T L H V I K S D L V N E E A T G Q F R V -

TACCCCGAGCTGCCAAGCCCTCATCTCAGCAACAACTCCAAACCCGTGGAGGACAAG
 421 -----+-----+-----+-----+-----+-----+-----+ 480
 ATGGGCCTCGACGGGTTGGAGGTAGAGTCGTTGAGGTTGGCACCTCCTGTT

a Y P E L P K P S I S S N N S K P V E D K -

GATGCTGTGGCCTTCACCTGTGAACCTGAGACTCAGGACCAACCTACCTGTGGTGGTA
 481 -----+-----+-----+-----+-----+-----+-----+ 540
 CTACGACACCGGAAGTGGACACTGGACTCTGAGTCCTGCGTTGGATGGACACCACCAT

a D A V A F T C E P E T Q D A T Y L W W V -

AACAAATCAGAGCCTCCGGTCAGTCCCAGGCTGCAGCTGCCAATGGCAACAGGACCTC
 541 -----+-----+-----+-----+-----+-----+-----+ 600
 TTGTAGTCTCGGAGGGCAGTCAGGGTCCGACGTCGACAGGTTACCGTGTGCTGGAG

a N N Q S L P V S P R L Q L S N G N R T L -

ACTCTATTCAATGTCACAAGAAATGACACAGCAAGCTACAAATGTGAAACCCAGAACCA
 601 -----+-----+-----+-----+-----+-----+-----+ 660
 TGAGATAAGTTACAGTGTCTTACTGTGTCGTTGATGTTACACTTGGTCTTGGGT

a T L F N V T R N D T A S Y K C E T Q N P -

GTGAGTGCAGGGCGAGTGTGATTCACTCTGAATGTCCTCTATGGCCGGATGCC
 661 -----+-----+-----+-----+-----+-----+-----+ 720
 CACTCACGGTCCCGCGTCACTAAGTCAGTAGGACTTACAGGAGATAACCGGGCTACGGGG

a V S A R R S D S V I L N V L Y G P D A P -

Figure 8

ACCATTTCCCTCTAAACACATCTTACAGATCAGGGAAAATCTGAACCTCTCCTGCCAC
 721 -----+-----+-----+-----+-----+-----+-----+ 780
 TGGTAAAGGGGAGATTGTGAGAATGTCTAGTCCCCTTAGACTTGAGAGGACGGTG

 a T I S P L N T S Y R S G E N L N L S C H -

 CGACCTCTAACCCACCTGCACAGTACTCTGGTTGTCAATGGGACTTCAGCAATCC
 781 -----+-----+-----+-----+-----+-----+-----+ 840
 CGTCGGAGATTGGTGGACGTGTCATGAGAACAAACAGTTACCCCTGAAAGGTGTTAGG

 a A A S N P P A Q Y S W F V N G T F Q Q S -

 ACCAAGAGCTTTATCCCCAACATCACTGTGAATAATAGTGGATCCTATACGTGCCAA
 841 -----+-----+-----+-----+-----+-----+-----+ 900
 TGGTTCTCGAGAAATAGGGTTGAGACACTTATTACACCTAGGATATGCACGGTT

 a T Q E L F I P N I T V N N S G S Y T C Q -

 GCCCATAACTCAGACACTGGCCTCAATAGGACCACAGTCACGACGATCACAGTCTATGAG
 901 -----+-----+-----+-----+-----+-----+-----+ 960
 CGGGTATTGAGTCTGTGACCGGAGTTATCCTGGTGTAGTGCTGCTAGTGTCAAGATACTC

 a A H N S D T G L N R T T V T T I T V Y E -

 CAACCCAAACCTTCATCACCAAGCAACAACTCCAACCCGGAGGATGAGGATGCTGTA
 961 -----+-----+-----+-----+-----+-----+-----+ 1020
 GGTGGGTTGGGAAGTAGTGGTCGTTGAGGTTGGGCACCTCCTACTCCTACGACAT

 a P P K P F I T S N N S N P V E D E D A V -

 GCCTTAACCTGTGAACCTGAGATTCAAACACAACCTACCTGTGGTGGTAAATAATCAG
 1021 -----+-----+-----+-----+-----+-----+-----+ 1080
 CGGAATTGGACACTGGACTCTAAGTCTGTGGATGGACACCACCCATTATTAGTC

 a A L T C E P E I Q N T T Y L W W V N N Q -

 AGCCTCCCGGTAGTCCCAGGCTGCAGCTGCCAATGACAACAGGACCCACTCTACTC
 1081 -----+-----+-----+-----+-----+-----+-----+ 1140
 TCGGAGGGCCAGTCAGGGTCCGACGTGACAGGTTACTGTTGCTGGAGTGAGATGAG

 a S L P V S P R L Q L S N D N R T L T L L -

 AGTGTACAAGGAATGATGAGGACCTATGAGTGTGGAATCCAGAACGAATTAAAGTGT
 1141 -----+-----+-----+-----+-----+-----+-----+ 1200
 TCACAGTGTCTTACTACATCCTGGATACTCACACCTTAGGTCTGCTTAATTCAA

 a S V T R N D V G P Y E C G I Q N E L S V -

 GACCACAGCGACCCAGTCATCCTGAATGCTCTATGGCCAGACGACCCCCACCATTCC
 1201 -----+-----+-----+-----+-----+-----+-----+ 1260
 CTGGTGTGCTGGTCAGTAGGACTTACAGGAGATACCGGTCTGCTGGGTGGTAAAGG

 a D H S D P V I L N V L Y G P D D P T I S -

 CCCTCATACACCTATTACCGTCCAGGGGTGAACCTCAGCTCTCCTGCCATGCAGCCTCT
 1261 -----+-----+-----+-----+-----+-----+-----+ 1320
 GGGAGTATGTGGATAATGGCAGGTCCCCACTTGGAGTCGGAGAGGACGGTACGTGGAGA

 a P S Y T Y Y R P G V N L S L S C H A A S -

 AACCCACCTGCACAGTATTCTGGCTGATTGATGGAACATCCAGAACACACACAAGAG
 1321 -----+-----+-----+-----+-----+-----+-----+ 1380
 TTGGGTGGACGTGTCATAAGAACCGACTAACTACCCCTTAGGTGTTGTTCTC

 a N P P A Q Y S W L I D G N I Q Q H T Q E -

 CTCTTTATCTCCAACATCACTGAGAAGAACAGCGGACTCTATACCTGCCAGGCCAAATAAC
 1381 -----+-----+-----+-----+-----+-----+-----+ 1440
 GAGAAATAGAGGGTAGTGACTCTCTGCGCTGAGATATGGACGGTCCGGTTATTG

 a L F I S N I T E K N S G L Y T C Q A N N -

Figure 8, con't

TCAGCCAGTGGCCACAGCAGGACTACAGTCAGAACATCACAGTCTCGGGAGCTGCC
 1441 -----+-----+-----+-----+-----+-----+ 1500
 AGTCGGTCACCGGTGTCGTCCTGATGTCAGTTCTGTTAGTGTCAAGAGACGCCCGACACGGG

 a S A S G H S R T T V K T I T V S A E L P -

 AAGCCCTCATCTCCAGCAACAACTCCAAACCGTGGAGGACAAGGATGCTGTGGCCTTC
 1501 -----+-----+-----+-----+-----+-----+ 1560
 TTCGGGAGGTAGAGGTCGTTGTTGAGGTTGGCACCTCTGTTCCACGACACCGGAAG

 a K P S I S S N N S K P V E D K D A V A F -

 ACCTGTGAACCTGAGGCTCAGAACACAAACCTACCTGTGGTGGTAAATGGTCAGAGCCTC
 1561 -----+-----+-----+-----+-----+-----+ 1620
 TGGACACTTGGACTCCGAGTCTTGTGTTGGATGGACACCACCCATTACAGTCTCGGAG

 a T C E P E A Q N T T Y L W W V N G Q S L -

 CCAGTCAGTCCCAGGCTGCAGCTGTCCAATGGCAACAGGACCCCTCACTCTATTCAATGTC
 1621 -----+-----+-----+-----+-----+-----+ 1680
 GGTCAAGTCAGGGTCCGACGTGACAGGTTACCGTTGTCCTGGAGTGAGATAAGTTACAG

 a P V S P R L Q L S N G N R T L T L F N V -

 ACAAGAAAATGACGCAAGAGCCTATGTATGTGAATCCAGAACTCAGTGAGTGCAAACCGC
 1681 -----+-----+-----+-----+-----+-----+ 1740
 TGTTCTTACTGCGTTCTCGGATACATACACCTTAGGTCTTGAGTCACTCACGTTGGCG

 a T R N D A R A Y V C G I Q N S V S A N R -

 AGTGACCCAGTCACCCCTGGATGTCCTCTATGGGCCGGACACCCCCCATTTCCCCCCC
 1741 -----+-----+-----+-----+-----+-----+ 1800
 TCACTGGGTCAAGTGGGACCTACAGGAGATAACCCGGCTGTGGGGTAGTAAAGGGGGGT

 a S D P V T L D V L Y G P D T P I I S P P -

 GACTCGCTTACCTTTCGGAGCGGACCTCAACCTCTCCCTGCCACTCGGCCTCTAACCCA
 1801 -----+-----+-----+-----+-----+-----+ 1860
 CTGAGCAGAATGAAAGCCCTCGCCTGGAGTTGGAGAGGACGGTGAGCCGGAGATTGGGT

 a D S S Y L S G A D L N L S C H S A S N P -

 TCCCCCGAGTATTCTTGGCGTATCAATGGGATACCGCAGCAACACACACAAGTTCTCTT

 1861 -----+-----+-----+-----+-----+-----+ 1920
 AGGGGCGTCATAAGAACCGCATAGTTACCCCTATGGCGTCGGTGTGTCAAGAGAAA

 a S P Q Y S W R I N G I P Q Q H T Q V L F -

 ATCGCCAAAATCAGCCAAATAATAACGGGACCTATGCCCTGGTTGTCTCTAACCTGGCT
 1921 -----+-----+-----+-----+-----+-----+ 1980
 TAGCGGTTTAGTGCGGTTATTATGCCCTGGATACGGACAAACAGAGATTGAACCGA

 a I A K I T P N N N G T Y A C F V S N L A -

 ACTGGCCGCAATAATTCCATAGTCAGAGCATCACAGTCTCTGCATCTGGAACTTCTCCT
 1981 -----+-----+-----+-----+-----+-----+ 2040
 TGACCGCGTTATTAAGGTATCAGTTCTCGTAGTGTCAAGAGACGTAGACCTTGAAGAGGA

 a T G R N N S I V K S I T V S A S G T S P -

 GGTCTCTCAGCTGGGCCACTGTCGGCATCATGATTGGAGTGTGGTTGGGGTTGCTCTG
 2041 -----+-----+-----+-----+-----+-----+ 2100
 CCAGAGAGTCGACCCCGGTACAGCGTAGTACTAACCTCACGACCAACCCAACGAGAC

 a G L S A G A T V G I M I G V L V G V A L -

 ATATAG ←
 2101 ----- 2106
 TATATC

 a I * ←

Figure 8, con't